Page last updated: 2024-10-24

chloroquine and Drug-Related Side Effects and Adverse Reactions

chloroquine has been researched along with Drug-Related Side Effects and Adverse Reactions in 65 studies

Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.

Drug-Related Side Effects and Adverse Reactions: Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.

Research Excerpts

Excerpt	Relevance	Reference
"A randomized controlled trial was conducted in 3 district hospitals in Sabah, Malaysia to compare the efficacy of AL against chloroquine (CQ) for uncomplicated knowlesi malaria."	9.27	Artemether-Lumefantrine Versus Chloroquine for the Treatment of Uncomplicated Plasmodium knowlesi Malaria: An Open-Label Randomized Controlled Trial CAN KNOW. ( Anstey, NM; Barber, BE; Chandna, A; Grigg, MJ; Menon, J; Patel, K; Price, RN; Rajahram, GS; Schimann, E; Wilkes, CS; William, T; Yeo, TW, 2018)
"Chloroquine-induced pruritus has been described as a common adverse event in African patients being treated for Plasmodium falciparum malaria, and has been associated with treatment discontinuation in this setting."	7.79	Prevalence and risk factors associated to pruritus in Plasmodium vivax patients using chloroquine in the Brazilian Amazon. ( Alecrim, MG; Alexandre, MA; Ballut, PC; Lacerda, MV; Orlando, AC; Siqueira, AM, 2013)
"Pyronaridine was non-inferior to chloroquine: treatment difference -0."	6.76	Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. ( Borghini-Fuhrer, I; Duparc, S; Fleckenstein, L; Poravuth, Y; Purnama, A; Pyae Phyo, A; Rao, BH; Rueangweerayut, R; Shin, CS; Socheat, D; Tjitra, E; Uthaisin, C; Valecha, N, 2011)
"A randomized controlled trial was conducted in 3 district hospitals in Sabah, Malaysia to compare the efficacy of AL against chloroquine (CQ) for uncomplicated knowlesi malaria."	5.27	Artemether-Lumefantrine Versus Chloroquine for the Treatment of Uncomplicated Plasmodium knowlesi Malaria: An Open-Label Randomized Controlled Trial CAN KNOW. ( Anstey, NM; Barber, BE; Chandna, A; Grigg, MJ; Menon, J; Patel, K; Price, RN; Rajahram, GS; Schimann, E; Wilkes, CS; William, T; Yeo, TW, 2018)
"Chloroquine-induced pruritus has been described as a common adverse event in African patients being treated for Plasmodium falciparum malaria, and has been associated with treatment discontinuation in this setting."	3.79	Prevalence and risk factors associated to pruritus in Plasmodium vivax patients using chloroquine in the Brazilian Amazon. ( Alecrim, MG; Alexandre, MA; Ballut, PC; Lacerda, MV; Orlando, AC; Siqueira, AM, 2013)
"To perform a systematic review on the psychiatric adverse effects of chloroquine (CQ) and hydroxychloroquine (HCQ); to summarize what is known about psychiatric adverse effects of these drugs; to compare clinical trials, populational studies, and case report studies; and to increase awareness of the potential psychiatric adverse effects of these drugs."	3.01	Systematic Review of Psychiatric Adverse Effects Induced by Chloroquine and Hydroxychloroquine: Case Reports and Population Studies. ( Cao, B; Chakravarty, S; Greenshaw, AJ; Liu, YS; Passos, IC; Talarico, F, 2023)
" In addition to the ongoing research and development of vaccines, there is still a dire need for safe and effective drugs for the control and treatment against the SARS-CoV-2 virus infection."	2.82	Safety profile of COVID-19 drugs in a real clinical setting. ( Bhardwaj, M; Chiu, MN; Sah, SP, 2022)
"Pyronaridine was non-inferior to chloroquine: treatment difference -0."	2.76	Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. ( Borghini-Fuhrer, I; Duparc, S; Fleckenstein, L; Poravuth, Y; Purnama, A; Pyae Phyo, A; Rao, BH; Rueangweerayut, R; Shin, CS; Socheat, D; Tjitra, E; Uthaisin, C; Valecha, N, 2011)
" Typically, the doses were 2 to 5 times greater than the AAO recommendation (adjusted to weight) to avoid toxic retinopathy, the most undesirable ocular side effect."	2.72	What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects. ( Altemir-Gómez, I; Fambuena-Muedra, I; Hershko, S; Jiménez-García, M; Tobarra-López, A, 2021)
"We reviewed the most recent systemic drugs used in Belgium causing toxic corneal side effects."	2.44	[Toxic effects of medications on the cornea]. ( Ravet, O, 2007)
" Drug-related toxic effects on the retina described in humans and animals are unrelated to melanin binding: melanin binding and retinal toxicity are two separate entities, the latter being related to the intrinsic toxicity of the compound rather than its ability to bind."	2.40	Binding of drugs to eye melanin is not predictive of ocular toxicity. ( Davies, T; Hanton, G; Jezequel, S; Leblanc, B; Taradach, C, 1998)
"Phospholipidosis (PLD) is a lysosomal storage disorder induced by compounds, notably cationic amphiphilic drugs, which although reversible interferes with cellular phospholipids."	1.38	In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets. ( Atzpodien, EA; Csato, M; Doessegger, L; Fischer, H; Lenz, B; Schmitt, G; Singer, T, 2012)
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."	1.37	FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011)
"Psychosis is caused by interactions with other drugs or by pharmacogenetic vulnerabilities that cause heightened responses to chloroquine or mefloquine alone, mediated through dopamine, acetylcholine, serotonin, P-glycoprotein, inhibited cortical activity, deranged calcium homeostasis, and impaired synaptogenesis."	1.33	Drug interactions and pharmacogenetic reactions are the basis for chloroquine and mefloquine-induced psychosis. ( Alisky, JM; Chertkova, EL; Iczkowski, KA, 2006)
"In chloroquine-treated cells, the EC50 values were 110."	1.31	Evaluation of the cytotoxicity of selected systemic and intravitreally dosed drugs in the cultures of human retinal pigment epithelial cell line and of pig primary retinal pigment epithelial cells. ( Diehl, H; Engelke, M; Huhtala, A; Mäenpää, H; Mannerström, M; Mäntylä, E; Mäntylä, M; Marselos, M; Pappas, P; Salminen, L; Tähti, H; Toimela, T; Uusitalo, H; Zorn-Kruppa, M, 2002)
"All cases arose because of failure by physicians to avoid dosing above published safe levels."	1.31	Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. ( Browning, DJ, 2002)

Research

Studies (65)

Timeframe	Studies, this research(%)	All Research%
pre-1990	35 (53.85)	18.7374
1990's	2 (3.08)	18.2507
2000's	5 (7.69)	29.6817
2010's	13 (20.00)	24.3611
2020's	10 (15.38)	2.80

Authors

Authors	Studies
Pedersen, JM	1
Matsson, P	1
Bergström, CA	1
Norinder, U	1
Hoogstraate, J	1
Artursson, P	1
Chen, M	1
Vijay, V	1
Shi, Q	2
Liu, Z	4
Fang, H	2
Tong, W	2
Fischer, H	1
Atzpodien, EA	1
Csato, M	1
Doessegger, L	1
Lenz, B	1
Schmitt, G	1
Singer, T	1
Ding, D	2
Kelly, R	1
Sakatis, MZ	1
Reese, MJ	1
Harrell, AW	1
Taylor, MA	1
Baines, IA	1
Chen, L	4
Bloomer, JC	1
Yang, EY	1
Ellens, HM	1
Ambroso, JL	1
Lovatt, CA	1
Ayrton, AD	1
Clarke, SE	1
Morgan, RE	1
van Staden, CJ	1
Chen, Y	4
Kalyanaraman, N	1
Kalanzi, J	1
Dunn, RT	1
Afshari, CA	1
Hamadeh, HK	1
Chiu, MN	1
Bhardwaj, M	1
Sah, SP	1
Talarico, F	1
Chakravarty, S	1
Liu, YS	1
Greenshaw, AJ	1
Passos, IC	1
Cao, B	1
Aït Moussa, L	1
Tebaa, A	1
Alj, L	1
Sefiani, H	1
Meski, FZ	1
Khattabi, A	1
Soulaymani Bencheikh, R	1
Brest, P	1
Benzaquen, J	1
Klionsky, DJ	2
Hofman, P	1
Mograbi, B	1
Tang, D	1
Li, J	8
Zhang, R	1
Kang, R	1
Nguépy Keubo, FR	1
Mboua, PC	1
Djifack Tadongfack, T	1
Fokouong Tchoffo, E	1
Tasson Tatang, C	1
Ide Zeuna, J	1
Noupoue, EM	1
Tsoplifack, CB	1
Folefack, GO	1
Kettani, M	1
Bandelier, P	1
Huo, J	1
Li, H	4
Yu, D	1
Arulsamy, N	1
AlAbbad, S	1
Sardot, T	1
Lekashvili, O	1
Decato, D	1
Lelj, F	1
Alexander Ross, JB	1
Rosenberg, E	1
Nazir, H	1
Muthuswamy, N	1
Louis, C	1
Jose, S	1
Prakash, J	1
Buan, MEM	1
Flox, C	1
Chavan, S	1
Shi, X	1
Kauranen, P	1
Kallio, T	1
Maia, G	1
Tammeveski, K	1
Lymperopoulos, N	1
Carcadea, E	1
Veziroglu, E	1
Iranzo, A	1
M Kannan, A	1
Arunamata, A	1
Tacy, TA	1
Kache, S	1
Mainwaring, RD	1
Ma, M	1
Maeda, K	1
Punn, R	1
Noguchi, S	1
Hahn, S	3
Iwasa, Y	3
Ling, J	2
Voccio, JP	2
Kim, Y	3
Song, J	3
Bascuñán, J	2
Chu, Y	1
Tomita, M	1
Cazorla, M	1
Herrera, E	1
Palomeque, E	1
Saud, N	1
Hoplock, LB	1
Lobchuk, MM	1
Lemoine, J	1
Li, X	10
Henson, MA	1
Unsihuay, D	1
Qiu, J	1
Swaroop, S	1
Nagornov, KO	1
Kozhinov, AN	1
Tsybin, YO	1
Kuang, S	1
Laskin, J	1
Zin, NNINM	1
Mohamad, MN	1
Roslan, K	1
Abdul Wafi, S	1
Abdul Moin, NI	1
Alias, A	1
Zakaria, Y	1
Abu-Bakar, N	1
Naveed, A	1
Jilani, K	1
Siddique, AB	1
Akbar, M	1
Riaz, M	1
Mushtaq, Z	1
Sikandar, M	1
Ilyas, S	1
Bibi, I	1
Asghar, A	1
Rasool, G	1
Irfan, M	1
Li, XY	1
Zhao, S	1
Fan, XH	1
Chen, KP	1
Hua, W	1
Liu, ZM	1
Xue, XD	1
Zhou, B	1
Zhang, S	2
Xing, YL	1
Chen, MA	1
Sun, Y	1
Neradilek, MB	1
Wu, XT	1
Zhang, D	2
Huang, W	1
Cui, Y	1
Yang, QQ	1
Li, HW	1
Zhao, XQ	1
Hossein Rashidi, B	1
Tarafdari, A	1
Ghazimirsaeed, ST	1
Shahrokh Tehraninezhad, E	1
Keikha, F	1
Eslami, B	1
Ghazimirsaeed, SM	1
Jafarabadi, M	1
Silvani, Y	1
Lovita, AND	1
Maharani, A	1
Wiyasa, IWA	1
Sujuti, H	1
Ratnawati, R	1
Raras, TYM	1
Lemin, AS	1
Rahman, MM	1
Pangarah, CA	1
Kiyu, A	1
Zeng, C	2
Du, H	1
Lin, D	1
Jalan, D	1
Rubagumya, F	1
Hopman, WM	1
Vanderpuye, V	1
Lopes, G	1
Seruga, B	1
Booth, CM	1
Berry, S	1
Hammad, N	1
Sajo, EA	1
Okunade, KS	1
Olorunfemi, G	1
Rabiu, KA	1
Anorlu, RI	1
Xu, C	2
Xiang, Y	1
Xu, X	1
Zhou, L	2
Dong, X	1
Tang, S	1
Gao, XC	1
Wei, CH	1
Zhang, RG	1
Cai, Q	1
He, Y	1
Tong, F	1
Dong, JH	1
Wu, G	1
Dong, XR	1
Tang, X	1
Tao, F	1
Xiang, W	1
Zhao, Y	2
Jin, L	1
Tao, H	1
Lei, Y	1
Gan, H	1
Huang, Y	1
Shan, A	1
Zhao, H	2
Wu, M	2
Ma, Q	1
Wang, J	4
Zhang, E	1
Zhang, J	3
Li, Y	5
Xue, F	1
Deng, L	1
Liu, L	2
Yan, Z	2
Wang, Y	2
Meng, J	1
Chen, G	2
Anastassiadou, M	1
Bernasconi, G	1
Brancato, A	1
Carrasco Cabrera, L	1
Greco, L	1
Jarrah, S	1
Kazocina, A	1
Leuschner, R	1
Magrans, JO	1
Miron, I	1
Nave, S	1
Pedersen, R	1
Reich, H	1
Rojas, A	1
Sacchi, A	1
Santos, M	1
Theobald, A	1
Vagenende, B	1
Verani, A	1
Du, L	1
Liu, X	1
Ren, Y	1
Li, P	1
Jiao, Q	1
Meng, P	1
Wang, F	2
Wang, YS	1
Wang, C	3
Zhou, X	2
Wang, W	1
Wang, S	2
Hou, J	1
Zhang, A	1
Lv, B	1
Gao, C	1
Pang, D	1
Lu, K	1
Ahmad, NH	1
Wang, L	1
Zhu, J	2
Zhang, L	2
Zhuang, T	1
Tu, J	1
Zhao, Z	1
Qu, Y	1
Yao, H	1
Wang, X	5
Lee, DF	1
Shen, J	3
Wen, L	1
Huang, G	2
Xie, X	1
Zhao, Q	1
Hu, W	1
Zhang, Y	4
Wu, X	1
Lu, J	2
Li, M	1
Li, W	2
Wu, W	1
Du, F	1
Ji, H	1
Yang, X	2
Xu, Z	1
Wan, L	1
Wen, Q	1
Cho, CH	1
Zou, C	1
Xiao, Z	1
Liao, J	1
Su, X	1
Bi, Z	1
Su, Q	1
Huang, H	1
Wei, Y	2
Gao, Y	2
Na, KJ	1
Choi, H	1
Oh, HR	1
Kim, YH	1
Lee, SB	1
Jung, YJ	1
Koh, J	1
Park, S	1
Lee, HJ	1
Jeon, YK	1
Chung, DH	1
Paeng, JC	1
Park, IK	1
Kang, CH	1
Cheon, GJ	1
Kang, KW	1
Lee, DS	1
Kim, YT	1
Pajuelo-Lozano, N	1
Alcalá, S	1
Sainz, B	1
Perona, R	1
Sanchez-Perez, I	1
Logotheti, S	1
Marquardt, S	1
Gupta, SK	1
Richter, C	1
Edelhäuser, BAH	1
Engelmann, D	1
Brenmoehl, J	1
Söhnchen, C	1
Murr, N	1
Alpers, M	1
Singh, KP	1
Wolkenhauer, O	1
Heckl, D	1
Spitschak, A	1
Pützer, BM	1
Liao, Y	1
Cheng, J	1
Kong, X	1
Li, S	1
Zhang, M	4
Zhang, H	1
Yang, T	2
Dong, Y	1
Xu, Y	1
Yuan, Z	1
Cao, J	1
Zheng, Y	1
Luo, Z	1
Mei, Z	1
Yao, Y	1
Liang, C	1
Yang, H	1
Song, Y	1
Yu, K	1
Zhu, C	1
Huang, Z	1
Qian, J	1
Ge, J	1
Hu, J	2
Wang, H	2
Liu, Y	4
Mi, Y	1
Kong, H	1
Xi, D	1
Yan, W	1
Luo, X	1
Ning, Q	1
Chang, X	2
Zhang, T	2
Wang, Q	2
Rathore, MG	1
Reddy, K	1
Chen, H	1
Shin, SH	1
Ma, WY	1
Bode, AM	1
Dong, Z	1
Mu, W	1
Liu, C	3
Gao, F	1
Qi, Y	1
Lu, H	1
Zhang, X	4
Cai, X	1
Ji, RY	1
Hou, Y	3
Tian, J	2
Shi, Y	1
Ying, S	1
Tan, M	1
Feng, G	1
Kuang, Y	1
Chen, D	1
Wu, D	3
Zhu, ZQ	1
Tang, HX	1
Shi, ZE	1
Kang, J	1
Liu, Q	1
Qi, J	2
Mu, J	1
Cong, Z	1
Chen, S	2
Fu, D	1
Li, Z	2
Celestrin, CP	1
Rocha, GZ	1
Stein, AM	1
Guadagnini, D	1
Tadelle, RM	1
Saad, MJA	1
Oliveira, AG	1
Bianconi, V	1
Bronzo, P	1
Banach, M	1
Sahebkar, A	1
Mannarino, MR	1
Pirro, M	1
Patsourakos, NG	1
Kouvari, M	1
Kotidis, A	1
Kalantzi, KI	1
Tsoumani, ME	1
Anastasiadis, F	1
Andronikos, P	1
Aslanidou, T	1
Efraimidis, P	1
Georgiopoulos, A	1
Gerakiou, K	1
Grigoriadou-Skouta, E	1
Grigoropoulos, P	1
Hatzopoulos, D	1
Kartalis, A	1
Lyras, A	1
Markatos, G	1
Mikrogeorgiou, A	1
Myroforou, I	1
Orkopoulos, A	1
Pavlidis, P	1
Petras, C	1
Riga, M	1
Skouloudi, M	1
Smyrnioudis, N	1
Thomaidis, K	1
Tsikouri, GE	1
Tsikouris, EI	1
Zisimos, K	1
Vavoulis, P	1
Vitali, MG	1
Vitsas, G	1
Vogiatzidis, C	1
Chantanis, S	1
Fousas, S	1
Panagiotakos, DB	1
Tselepis, AD	1
Jungen, C	1
Alken, FA	1
Eickholt, C	1
Scherschel, K	1
Kuklik, P	1
Klatt, N	1
Schwarzl, J	1
Moser, J	1
Jularic, M	1
Akbulak, RO	1
Schaeffer, B	1
Willems, S	1
Meyer, C	1
Nowak, JK	1
Szczepanik, M	1
Trypuć, M	1
Pogorzelski, A	1
Bobkowski, W	1
Grytczuk, M	1
Minarowska, A	1
Wójciak, R	1
Walkowiak, J	1
Lu, Y	1
Xi, J	1
Li, C	1
Chen, W	2
Hu, X	1
Zhang, F	1
Wei, H	1
Wang, Z	1
Gurzu, S	1
Jung, I	1
Sugimura, H	2
Stefan-van Staden, RI	1
Yamada, H	1
Natsume, H	1
Iwashita, Y	1
Szodorai, R	1
Szederjesi, J	1
Yari, D	1
Ehsanbakhsh, Z	1
Validad, MH	1
Langroudi, FH	1
Esfandiari, H	1
Prager, A	1
Hassanpour, K	1
Kurup, SP	1
Mets-Halgrimson, R	1
Yoon, H	1
Zeid, JL	1
Mets, MB	1
Rahmani, B	1
Araujo-Castillo, RV	1
Culquichicón, C	1
Solis Condor, R	1
Efendi, F	1
Sebayang, SK	1
Astutik, E	1
Hadisuyatmana, S	1
Has, EMM	1
Kuswanto, H	1
Foroutan, T	1
Ahmadi, F	1
Moayer, F	1
Khalvati, S	1
Zhang, Q	2
Lyu, Y	1
Huang, J	1
Yu, N	1
Wen, Z	1
Hou, H	1
Zhao, T	1
Gupta, A	1
Khosla, N	1
Govindasamy, V	1
Saini, A	1
Annapurna, K	1
Dhakate, SR	1
Akkaya, Ö	1
Chandgude, AL	1
Dömling, A	1
Harnett, J	1
Oakes, K	1
Carè, J	1
Leach, M	1
Brown, D	1
Cramer, H	1
Pinder, TA	1
Steel, A	1
Anheyer, D	1
Cantu, J	1
Valle, J	1
Flores, K	1
Gonzalez, D	1
Valdes, C	1
Lopez, J	1
Padilla, V	1
Alcoutlabi, M	1
Parsons, J	1
Núñez, K	1
Hamed, M	1
Fort, D	1
Bruce, D	1
Thevenot, P	1
Cohen, A	1
Weber, P	1
Menezes, AMB	1
Gonçalves, H	1
Perez-Padilla, R	1
Jarvis, D	1
de Oliveira, PD	1
Wehrmeister, FC	1
Mir, S	1
Wong, J	1
Ryan, CM	1
Bellingham, G	1
Singh, M	2
Waseem, R	1
Eckert, DJ	1
Chung, F	1
Hegde, H	1
Shimpi, N	1
Panny, A	1
Glurich, I	1
Christie, P	1
Acharya, A	1
English, KL	1
Downs, M	1
Goetchius, E	1
Buxton, R	1
Ryder, JW	1
Ploutz-Snyder, R	1
Guilliams, M	1
Scott, JM	1
Ploutz-Snyder, LL	1
Martens, C	1
Goplen, FK	1
Aasen, T	1
Gjestad, R	1
Nordfalk, KF	1
Nordahl, SHG	1
Inoue, T	1
Soshi, S	1
Kubota, M	1
Marumo, K	1
Mortensen, NP	1
Caffaro, MM	1
Patel, PR	2
Uddin, MJ	1
Aravamudhan, S	1
Sumner, SJ	1
Fennell, TR	1
Gal, RL	1
Cohen, NJ	1
Kruger, D	1
Beck, RW	1
Bergenstal, RM	1
Calhoun, P	1
Cushman, T	1
Haban, A	1
Hood, K	1
Johnson, ML	1
McArthur, T	1
Olson, BA	1
Weinstock, RS	1
Oser, SM	1
Oser, TK	1
Bugielski, B	1
Strayer, H	1
Aleppo, G	1
Maruyama, H	1
Hirayama, K	1
Yamashita, M	1
Ohgi, K	1
Tsujimoto, R	1
Takayasu, M	1
Shimohata, H	1
Kobayashi, M	1
Buscagan, TM	1
Rees, DC	1
Jaborek, JR	1
Zerby, HN	1
Wick, MP	1
Fluharty, FL	1
Moeller, SJ	1
Razavi, P	1
Dickler, MN	1
Shah, PD	1
Toy, W	1
Brown, DN	1
Won, HH	1
Li, BT	1
Shen, R	1
Vasan, N	1
Modi, S	1
Jhaveri, K	1
Caravella, BA	1
Patil, S	1
Selenica, P	1
Zamora, S	1
Cowan, AM	1
Comen, E	1
Singh, A	1
Covey, A	1
Berger, MF	1
Hudis, CA	1
Norton, L	1
Nagy, RJ	1
Odegaard, JI	1
Lanman, RB	1
Solit, DB	1
Robson, ME	1
Lacouture, ME	1
Brogi, E	1
Reis-Filho, JS	1
Moynahan, ME	1
Scaltriti, M	1
Chandarlapaty, S	1
Papouskova, K	1
Moravcova, M	1
Masrati, G	1
Ben-Tal, N	1
Sychrova, H	1
Zimmermannova, O	1
Fang, J	1
Fan, Y	1
Luo, T	2
Su, H	1
Tsetseris, L	1
Anthopoulos, TD	1
Liu, SF	1
Zhao, K	1
Sacan, O	1
Turkyilmaz, IB	1
Bayrak, BB	1
Mutlu, O	1
Akev, N	1
Yanardag, R	1
Gruber, S	1
Kamnoedboon, P	1
Özcan, M	1
Srinivasan, M	1
Jo, YH	1
Oh, HK	1
Jeong, SY	1
Lee, BG	1
Zheng, J	1
Guan, H	1
Li, D	2
Tan, H	1
Maji, TK	1
J R, A	1
Mukherjee, S	1
Alexander, R	1
Mondal, A	1
Das, S	1
Sharma, RK	1
Chakraborty, NK	1
Dasgupta, K	1
Sharma, AMR	1
Hawaldar, R	1
Pandey, M	1
Naik, A	1
Majumdar, K	1
Pal, SK	1
Adarsh, KV	1
Ray, SK	1
Karmakar, D	1
Ma, Y	2
Gao, W	1
Ma, S	1
Lin, W	1
Zhou, T	1
Wu, T	1
Wu, Q	1
Ye, C	1
He, X	1
Jiang, F	1
Yuan, D	1
Chen, Q	1
Hong, M	1
Chen, K	1
Hussain, M	1
Razi, SS	1
Yildiz, EA	1
Zhao, J	1
Yaglioglu, HG	1
Donato, MD	1
Jiang, J	1
Jamil, MI	1
Zhan, X	1
Chen, F	1
Cheng, D	1
Wu, CT	1
Utsunomiya, T	1
Ichii, T	1
Fujinami, S	1
Nakajima, K	1
Sanchez, DM	1
Raucci, U	1
Ferreras, KN	1
Martínez, TJ	1
Mordi, NA	1
Mordi, IR	1
Singh, JS	1
McCrimmon, RJ	1
Struthers, AD	1
Lang, CC	1
Wang, XW	1
Yuan, LJ	1
Yang, Y	1
Chen, WF	1
Luo, R	1
Yang, K	1
Amarasiri, SS	1
Attanayake, AP	1
Arawwawala, LDAM	1
Jayatilaka, KAPW	1
Mudduwa, LKB	1
Ogunsuyi, O	2
Akanni, O	1
Alabi, O	1
Alimba, C	1
Adaramoye, O	1
Cambier, S	1
Eswara, S	1
Gutleb, AC	1
Bakare, A	1
Gu, Z	1
Cong, J	1
Pellegrini, M	1
Palmieri, S	1
Ricci, A	1
Serio, A	1
Paparella, A	1
Lo Sterzo, C	1
Jadeja, SD	1
Vaishnav, J	1
Mansuri, MS	1
Shah, C	1
Mayatra, JM	1
Shah, A	1
Begum, R	1
Song, H	2
Lian, Y	1
Wan, T	1
Schultz-Lebahn, A	1
Skipper, MT	1
Hvas, AM	1
Larsen, OH	1
Hijazi, Z	1
Granger, CB	1
Hohnloser, SH	1
Westerbergh, J	1
Lindbäck, J	1
Alexander, JH	1
Keltai, M	1
Parkhomenko, A	1
López-Sendón, JL	1
Lopes, RD	1
Siegbahn, A	1
Wallentin, L	1
El-Tarabany, MS	1
Saleh, AA	1
El-Araby, IE	1
El-Magd, MA	1
van Ginkel, MPH	1
Schijven, MP	1
van Grevenstein, WMU	1
Schreuder, HWR	1
Pereira, EDM	1
da Silva, J	1
Carvalho, PDS	1
Grivicich, I	1
Picada, JN	1
Salgado Júnior, IB	1
Vasques, GJ	1
Pereira, MADS	1
Reginatto, FH	1
Ferraz, ABF	1
Vasilenko, EA	1
Gorshkova, EN	1
Astrakhantseva, IV	1
Drutskaya, MS	1
Tillib, SV	1
Nedospasov, SA	1
Mokhonov, VV	1
Nam, YW	1
Cui, M	1
Orfali, R	1
Viegas, A	1
Nguyen, M	1
Mohammed, EHM	1
Zoghebi, KA	1
Rahighi, S	1
Parang, K	1
Patterson, KC	1
Kahanovitch, U	1
Gonçalves, CM	1
Hablitz, JJ	1
Staruschenko, A	1
Mulkey, DK	1
Olsen, ML	1
Gu, L	1
Cao, X	1
Mukhtar, A	1
Wu, K	1
Zhang, YY	1
Zhu, Y	1
Lu, DZ	1
Dong, W	1
Bi, WJ	1
Feng, XJ	1
Wen, LM	1
Sun, H	1
Qi, MC	1
Chang, CC	1
Dinh, TK	1
Lee, YA	1
Wang, FN	1
Sung, YC	1
Yu, PL	1
Chiu, SC	1
Shih, YC	1
Wu, CY	1
Huang, YD	1
Lu, TT	1
Wan, D	1
Sakizadeh, J	1
Cline, JP	1
Snyder, MA	1
Kiely, CJ	1
McIntosh, S	1
Jiang, X	1
Cao, JW	1
Zhao, CK	1
Yang, R	1
Zhang, QY	1
Chen, KJ	2
Liu, H	1
He, Z	1
Chen, B	1
Wu, J	1
Du, X	1
Moore, J	1
Blank, BR	1
Eksterowicz, J	1
Sutimantanapi, D	1
Yuen, N	1
Metzger, T	1
Chan, B	1
Huang, T	1
Chen, X	1
Duong, F	1
Kong, W	1
Chang, JH	1
Sun, J	1
Zavorotinskaya, T	1
Ye, Q	1
Junttila, MR	1
Ndubaku, C	1
Friedman, LS	1
Fantin, VR	1
Sun, D	1
Fei, P	1
Xie, Q	1
Jiang, Y	1
Feng, H	1
Chang, Y	1
Kang, H	1
Xing, M	1
Chen, J	1
Shao, Z	1
Yuan, C	1
Wu, Y	1
Allan, R	1
Canham, K	1
Wallace, R	1
Singh, D	1
Ward, J	1
Cooper, A	1
Newcomb, C	1
Nammour, S	1
El Mobadder, M	1
Maalouf, E	1
Namour, M	1
Namour, A	1
Rey, G	1
Matamba, P	1
Matys, J	1
Zeinoun, T	1
Grzech-Leśniak, K	1
Segabinazi Peserico, C	1
Garozi, L	1
Zagatto, AM	1
Machado, FA	1
Hirth, JM	1
Dinehart, EE	1
Lin, YL	1
Kuo, YF	1
Nouri, SS	1
Ritchie, C	1
Volow, A	1
Li, B	2
McSpadden, S	1
Dearman, K	1
Kotwal, A	1
Sudore, RL	1
Ward, L	1
Thakur, A	1
Kondadasula, SV	1
Ji, K	1
Schalk, DL	1
Bliemeister, E	1
Ung, J	1
Aboukameel, A	1
Casarez, E	1
Sloane, BF	1
Lum, LG	1
Xiao, M	1
Feng, X	1
Gao, R	1
Du, B	1
Brooks, T	1
Zwirner, J	1
Hammer, N	1
Ondruschka, B	1
Jermy, M	1
Luengo, A	1
Marzo, I	1
Reback, M	1
Daubit, IM	1
Fernández-Moreira, V	1
Metzler-Nolte, N	1
Gimeno, MC	1
Tonchev, I	1
Heberman, D	1
Peretz, A	1
Medvedovsky, AT	1
Gotsman, I	1
Rashi, Y	1
Poles, L	1
Goland, S	1
Perlman, GY	1
Danenberg, HD	1
Beeri, R	1
Shuvy, M	1
Fu, Q	1
Yang, D	1
Sarapulova, A	1
Pang, Q	1
Meng, Y	1
Wei, L	1
Ehrenberg, H	1
Kim, CC	1
Jeong, SH	1
Oh, KH	1
Nam, KT	1
Sun, JY	1
Ning, J	1
Duan, Z	1
Kershaw, SV	1
Rogach, AL	1
Gao, Z	1
Wang, T	1
Li, Q	1
Cao, T	1
Guo, L	1
Fu, Y	1
Seeger, ZL	1
Izgorodina, EI	1
Hue, S	1
Beldi-Ferchiou, A	1
Bendib, I	1
Surenaud, M	1
Fourati, S	1
Frapard, T	1
Rivoal, S	1
Razazi, K	1
Carteaux, G	1
Delfau-Larue, MH	1
Mekontso-Dessap, A	1
Audureau, E	1
de Prost, N	1
Gao, SS	1
Duangthip, D	1
Lo, ECM	1
Chu, CH	1
Roberts, W	1
Rosenheck, RA	1
Miyake, T	1
Kimoto, E	1
Luo, L	1
Mathialagan, S	1
Horlbogen, LM	1
Ramanathan, R	1
Wood, LS	1
Johnson, JG	1
Le, VH	1
Vourvahis, M	1
Rodrigues, AD	1
Muto, C	1
Furihata, K	1
Sugiyama, Y	1
Kusuhara, H	1
Gong, Q	1
Song, W	1
Sun, B	1
Cao, P	1
Gu, S	1
Sun, X	1
Zhou, G	1
Toma, C	1
Khandhar, S	1
Zalewski, AM	1
D'Auria, SJ	1
Tu, TM	1
Jaber, WA	1
Cho, J	2
Suwandaratne, NS	1
Razek, S	1
Choi, YH	1
Piper, LFJ	1
Watson, DF	1
Banerjee, S	1
Xie, S	1
Lindsay, AP	1
Bates, FS	1
Lodge, TP	1
Hao, Y	1
Chapovetsky, A	1
Liu, JJ	1
Welborn, M	1
Luna, JM	1
Do, T	1
Haiges, R	1
Miller Iii, TF	1
Marinescu, SC	1
Lopez, SA	1
Compter, I	1
Eekers, DBP	1
Hoeben, A	1
Rouschop, KMA	1
Reymen, B	1
Ackermans, L	1
Beckervordersantforth, J	1
Bauer, NJC	1
Anten, MM	1
Wesseling, P	1
Postma, AA	1
De Ruysscher, D	1
Lambin, P	1
Qiang, L	1
Yang, S	1
Cui, YH	1
He, YY	1
Kumar, SK	1
Jacobus, SJ	1
Cohen, AD	1
Weiss, M	1
Callander, N	1
Singh, AK	1
Parker, TL	1
Menter, A	1
Parsons, B	1
Kumar, P	1
Kapoor, P	1
Rosenberg, A	1
Zonder, JA	1
Faber, E	1
Lonial, S	1
Anderson, KC	1
Richardson, PG	1
Orlowski, RZ	1
Wagner, LI	1
Rajkumar, SV	1
Li, G	1
Hou, G	1
Cui, J	1
Xie, H	1
Sun, Z	1
Fang, Z	1
Dunstand-Guzmán, E	1
Hallal-Calleros, C	1
Hernández-Velázquez, VM	1
Canales-Vargas, EJ	1
Domínguez-Roldan, R	1
Pedernera, M	1
Peña-Chora, G	1
Flores-Pérez, I	1
Kim, MJ	1
Han, C	1
White, K	1
Park, HJ	1
Boyd, K	1
Rothenberger, C	1
Bose, U	1
Carmichael, P	1
Linser, PJ	1
Tanokura, M	1
Salvi, R	1
Someya, S	1
Samuni, A	1
Goldstein, S	1
Divya, KP	1
Dharuman, V	1
Feng, J	2
Qian, Y	1
Cheng, Q	1
Ma, H	1
Ren, X	1
Wei, Q	1
Pan, W	1
Guo, J	1
Situ, B	1
An, T	1
Zheng, L	1
Augusto, S	1
Ratola, N	1
Tarín-Carrasco, P	1
Jiménez-Guerrero, P	1
Turco, M	1
Schuhmacher, M	1
Costa, S	1
Teixeira, JP	1
Costa, C	1
Syed, A	1
Marraiki, N	1
Al-Rashed, S	1
Elgorban, AM	1
Yassin, MT	1
Chankhanittha, T	1
Nanan, S	1
Sorokina, KN	1
Samoylova, YV	1
Gromov, NV	1
Ogorodnikova, OL	1
Parmon, VN	1
Ye, J	1
Liao, W	1
Zhang, P	1
Nabi, M	1
Cai, Y	1
Li, F	1
Alsbou, EM	1
Omari, KW	1
Adeosun, WA	1
Asiri, AM	1
Marwani, HM	1
Barral, M	1
Jemal-Turki, A	1
Beuvon, F	1
Soyer, P	1
Camparo, P	1
Cornud, F	1
Atwater, BD	1
Jones, WS	1
Loring, Z	1
Friedman, DJ	1
Namburath, M	1
Papirio, S	1
Moscariello, C	1
Di Costanzo, N	1
Pirozzi, F	1
Alappat, BJ	1
Sreekrishnan, TR	1
Volpin, F	1
Woo, YC	1
Kim, H	1
Freguia, S	1
Jeong, N	1
Choi, JS	1
Phuntsho, S	1
Shon, HK	1
Domínguez-Zambrano, E	1
Pedraza-Chaverri, J	1
López-Santos, AL	1
Medina-Campos, ON	1
Cruz-Rivera, C	1
Bueno-Hernández, F	1
Espinosa-Cuevas, A	1
Bulavaitė, A	1
Dalgediene, I	1
Michailoviene, V	1
Pleckaityte, M	1
Sauerbier, P	1
Köhler, R	1
Renner, G	1
Militz, H	1
Zekarias, A	1
Watson, S	1
Vidlin, SH	1
Grundmark, B	1
Wong, AO	1
Gurung, B	1
Wong, WS	1
Mak, SY	1
Tse, WW	1
Li, CM	1
Lieu, DK	1
Costa, KD	1
Li, RA	1
Hajjar, RJ	1
Perez, J	1
Roustit, M	1
Lepelley, M	1
Revol, B	1
Cracowski, JL	1
Khouri, C	1
Fambuena-Muedra, I	1
Jiménez-García, M	1
Hershko, S	1
Altemir-Gómez, I	1
Tobarra-López, A	1
Grigg, MJ	1
William, T	1
Barber, BE	1
Rajahram, GS	1
Menon, J	1
Schimann, E	1
Wilkes, CS	1
Patel, K	1
Chandna, A	1
Price, RN	1
Yeo, TW	1
Anstey, NM	1
Chasset, F	1
Arnaud, L	1
Jachiet, M	1
Monfort, JB	1
Bouaziz, JD	1
Cordoliani, F	1
Bagot, M	1
Barbaud, A	1
Francès, C	1
Ballut, PC	1
Siqueira, AM	1
Orlando, AC	1
Alexandre, MA	1
Alecrim, MG	1
Lacerda, MV	1
Leroux-Roels, G	1
Bourguignon, P	1
Willekens, J	1
Janssens, M	1
Clement, F	1
Didierlaurent, AM	1
Fissette, L	1
Roman, F	1
Boutriau, D	1
Al-Bari, MA	1
Poravuth, Y	1
Socheat, D	1
Rueangweerayut, R	1
Uthaisin, C	1
Pyae Phyo, A	1
Valecha, N	1
Rao, BH	1
Tjitra, E	1
Purnama, A	1
Borghini-Fuhrer, I	1
Duparc, S	1
Shin, CS	1
Fleckenstein, L	1
Kemgne, EA	1
Mbacham, WF	1
Boyom, FF	1
Zollo, PH	1
Tsamo, E	1
Rosenthal, PJ	1
Aki, T	1
Nara, A	1
Uemura, K	1
DE BELLEVAUX, JN	1
VANDERICK, F	1
CANN, HM	1
VERHULST, HL	1
ARDEN, GB	2
FRIEDMANN, A	1
KOLB, H	2
HENKIND, P	1
COPEMAN, PW	1
COWELL, TK	1
DALLAS, NL	1
FRANCOIS, J	1
DEBECKER, L	1
HENKES, HE	2
KJAER, K	1
MAYER, W	1
Alisky, JM	1
Chertkova, EL	1
Iczkowski, KA	1
Ravet, O	1
Pilger, IS	1
Khan, MA	1
Leblanc, B	1
Jezequel, S	1
Davies, T	1
Hanton, G	1
Taradach, C	1
Mannerström, M	1
Zorn-Kruppa, M	1
Diehl, H	1
Engelke, M	1
Toimela, T	1
Mäenpää, H	1
Huhtala, A	1
Uusitalo, H	1
Salminen, L	1
Pappas, P	1
Marselos, M	1
Mäntylä, M	1
Mäntylä, E	1
Tähti, H	1
Browning, DJ	1
Argov, Z	1
Mastaglia, FL	1
Mukherjee, DK	1
Mukherjee, K	1
Mayer, K	1
Bernstein, AH	1
Taylor, HG	1
Stein, CM	1
Jongeling, G	1
Potts, AM	1
Thurn, G	1
Koch, HR	1
Hockwin, O	1
Wurm, K	1
Tredici, TJ	1
Epstein, DL	1
Poskitt, EM	1
Robertson, DM	1
Käppeli, F	1
Bornstein, Y	1
Meltzer, AS	1
Meier-Ruge, W	2
Jaros, Z	1
Cerasoli, JR	1
Dodson, WH	1
Holley, HL	1
Fabre, J	1
Lendle, L	1
Hague, EB	1

Clinical Trials (6)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Artemether-lumefantrine vs Chloroquine in Patients With Acute Uncomplicated P. Knowlesi Malaria: a Randomized Open Label Trial in Sabah, Malaysia (CAN KNOW Trial)[NCT02001012]	Phase 3	123 participants (Actual)	Interventional	2014-01-31	Completed
A Study to Evaluate the Safety and Immunogenicity of a Booster Dose of GSK Biologicals' HIV Candidate Vaccine (732461) After Administration of Chloroquine in Healthy Adults.[NCT00972725]	Phase 2	28 participants (Actual)	Interventional	2009-12-01	Completed
A Dose-ranging Study to Compare the Safety and Immunogenicity of a Candidate Human Deficiency Virus (HIV) Vaccine 732461, Adjuvanted or Not, Administered According to a 0, 1 Month Schedule to Healthy Adult HIV Seronegative Volunteers.[NCT00434512]	Phase 2	180 participants (Actual)	Interventional	2007-02-20	Completed
Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography.[NCT02874287]	Phase 4	35 participants (Actual)	Interventional	2017-10-08	Completed
Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19[NCT04394416]	Phase 3	204 participants (Anticipated)	Interventional	2020-06-02	Active, not recruiting
A Phase III Comparative (Double-blind, Double-dummy) Randomised Multicentre Study to Assess the Safety & Efficacy of Oral Pyronaridine Artesunate (180:60 mg) Versus Chloroquine (155 mg) in Children & Adult Patients With Acute Vivax Malaria[NCT00440999]	Phase 3	456 participants (Actual)	Interventional	2007-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Subjects With AEs of Specific Interest and Immune-Mediated Disorders (IMDs)

Adverse events of specific interest include auto-immune diseases (AID) and immune mediated disorders such as neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, inflammatory bowel diseases, autoimmune blood disorders, inflammatory skin disorders, other autoimmune/inflammatory events. (NCT00972725)
Timeframe: During the entire study period (from Day 0 up to Day 360)

Intervention	Participants (Count of Participants)
GSK732461+Nivaquine Group	0
GSK732461 Group	0

Number of Subjects With Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. (NCT00972725)
Timeframe: During the entire study period (from Day 0 up to Day 360)

Intervention	Participants (Count of Participants)
GSK732461+Nivaquine Group	0
GSK732461 Group	0

Anti- RT, Nef, p17, p24 and F4co Antibody Concentrations

Antibody concentrations were expressed as geometric mean concentrations (GMCs), given in milli-enzyme-linked immunosorbent assay (ELISA) units per millilitre (mEL.U/mL). (NCT00972725)
Timeframe: At Day 0, 7, 14, 30 and 180

Intervention	mEL.U/mL (Geometric Mean)
	Anti-RT, Day 0	Anti-RT, Day 7	Anti-RT, Day 14	Anti-RT, Day 30	Anti-RT, Day 180	Anti-Nef, Day 0	Anti-Nef, Day 7	Anti-Nef, Day 14	Anti-Nef, Day 30	Anti-Nef, Day 180	Anti-p17, Day 0	Anti-p17, Day 7	Anti-p17, Day 14	Anti-p17, Day 30	Anti-p17, Day 180	Anti-p24, Day 0	Anti-p24, Day 7	Anti-p24, Day 14	Anti-p24, Day 30	Anti-p24, Day 180	Anti-F4co, Day 0	Anti-F4co, Day 7	Anti-F4co, Day 14	Anti-F4co, Day 30	Anti-F4co, Day 180
GSK732461 Group	198.4	39928.9	59932.0	57653.6	26520.6	536.3	38621.8	63283.3	42709.2	21371.8	98.9	1121.5	1763.3	1610.1	639.0	483.3	36200.9	59655.5	49619.3	27545.3	330.2	39948.9	63951.9	65633.5	40715.4
GSK732461+Nivaquine Group	154.0	31465.3	79774.0	71028.8	27286.9	394.6	38430.3	113387.2	77192.3	25141.1	93.5	1599.4	5069.8	5148.5	1115.5	377.4	31533.9	78313.7	61372.0	27590.9	217.8	37905.7	83863.4	74791.3	42847.4

Frequency of Antigen (F4co_est) Specific CD4+ T Cells Expressing at Least 2 Markers/ Cytokines

Cytokine/marker co-expression profile was defined as the antigen-specific CD4+ T cells expressing IL-2 and/or TNF-α and/or IFN-γ and/or CD40-L cytokines as determined by ICS. Determination of F4co was done by stimulating the F4 antigen with a peptide pool spanning (pool_F4co) or by adding individual frequencies of the CD4+ T cell response to each of the 4 antigens (F4co_est). (NCT00972725)
Timeframe: At Day 0, 7, 14, 30 and 180

Intervention	T cells/million cells (Median)																																			T cells/million cells (Median)
	F4co_est, CD40L+, D0	F4co_est, CD40L+, D7	F4co_est, CD40L+, D14	F4co_est, CD40L+, D30	F4co_est, CD40L+, D180	F4co_est, IL2+, D0	F4co_est, IL2+, D7	F4co_est, IL2+, D14	F4co_est, IL2+, D30	F4co_est, IL2+, D180	F4co_est, TNF+, D0	F4co_est, TNF+, D7	F4co_est, TNF+, D14	F4co_est, TNF+, D30	F4co_est, TNF+, D180	F4co_est, IFN+, D0	F4co_est, IFN+, D7	F4co_est, IFN+, D14	F4co_est, IFN+, D30	F4co_est, IFN+, D180	F4co_est, CD40L+IL2+, D0	F4co_est, CD40L+IL2+, D7	F4co_est, CD40L+IL2+, D14	F4co_est, CD40L+IL2+, D30	F4co_est, CD40L+IL2+, D180	F4co_est, CD40L+TNF+, D0	F4co_est, CD40L+TNF+, D7	F4co_est, CD40L+TNF+, D14	F4co_est, CD40L+TNF+, D30	F4co_est, CD40L+TNF+, D180	F4co_est, CD40L+IFN+, D0	F4co_est, CD40L+IFN+, D7	F4co_est, CD40L+IFN+, D14	F4co_est, CD40L+IFN+, D30	F4co_est, CD40L+IFN+, D180	F4co_est, IL2+TNF+, D0	F4co_est, IL2+TNF+, D7	F4co_est, IL2+TNF+, D14	F4co_est, IL2+TNF+, D30	F4co_est, IL2+TNF+, D180	F4co_est, IL2+IFN+, D0	F4co_est, IL2+IFN+, D7	F4co_est, IL2+IFN+, D14	F4co_est, IL2+IFN+, D30	F4co_est, IL2+IFN+, D180	F4co_est, TNF+IFN+, D0	F4co_est, TNF+IFN+, D7	F4co_est, TNF+IFN+, D14	F4co_est, TNF+IFN+, D30	F4co_est, TNF+IFN+, D180	F4co_est, CD40L+IL2+TNF+, D0	F4co_est, CD40L+IL2+TNF+, D7	F4co_est, CD40L+IL2+TNF+, D14	F4co_est, CD40L+IL2+TNF+, D30	F4co_est, CD40L+IL2+TNF+, D180	F4co_est, CD40L+IL2+IFN+, D0	F4co_est, CD40L+IL2+IFN+, D7	F4co_est, CD40L+IL2+IFN+, D14	F4co_est, CD40L+IL2+IFN+, D30	F4co_est, CD40L+IL2+IFN+, D180	F4co_est, CD40L+TNF+IFN+, D0	F4co_est, CD40L+TNF+IFN+, D7	F4co_est, CD40+TNF+IFN+, D14	F4co_est, CD40L+TNF+IFN+, D30	F4co_est, CD40L+TNF+IFN+, D180	F4co_est, IL2+TNF+IFN+, D0	F4co_est, IL2+TNF+IFN+, D7	F4co_est, IL2+TNF+IFN+, D14	F4co_est, IL2+TNF+IFN+, D30	F4co_est, IL2+TNF+IFN+, D180	F4co_est, CD40L+IL2+TNF+IFN+, D0	F4co_est, CD40L+IL2+TNF+IFN+, D7	F4co_est, CD40L+IL2+TNF+IFN+, D14	F4co_est, CD40L+IL2+TNF+IFN+, D30	F4co_est, CD40L+IL2+TNF+IFN+, D180
GSK732461 Group	270.50	2296.00	1108.00	697.00	507.00	138.00	165.00	92.00	134.00	93.00	129.50	635.00	477.00	608.00	40.50	42.00	93.00	71.00	30.00	36.50	761.50	2496.00	1860.00	1217.00	1309.50	95.00	591.00	596.00	234.00	63.50	9.00	127.00	60.00	61.00	30.00	34.50	86.00	49.00	82.00	87.50	4.00	12.00	4.00	4.00	17.00	14.00	72.00	64.00	86.00	59.50	972.50	3392.00	3279.00	2593.00	1288.50	45.00	254.00	157.00	139.00	104.00	8.50	111.00	85.00	44.00	22.50	4.00	30.00	17.00	27.00	30.00	138.00	512.00	601.00	384.00	244.00
GSK732461+Nivaquine Group	562.00	2050.50	1106.00	584.00	543.00	54.00	201.50	130.00	75.00	82.00	192.00	844.00	388.00	194.00	191.00	43.00	141.50	30.00	24.00	120.00	659.00	2048.00	1724.00	1042.00	1184.00	74.00	491.50	554.00	382.00	109.00	4.00	123.50	68.00	24.00	17.00	37.00	165.00	103.00	30.00	43.00	4.00	17.00	10.00	4.00	4.00	17.00	45.00	56.00	35.00	17.00	1050.00	1587.00	2652.00	2635.00	1088.00	51.00	158.50	107.00	46.00	123.00	4.00	86.50	82.00	43.00	16.00	4.00	21.00	17.00	4.00	25.00	107.00	348.00	457.00	284.00	134.00

Frequency of Antigen (F4co_est) Specific CD8+ T Cells Expressing at Least One Marker/ Cytokine

Cytokine/marker co-expression profile was defined as the antigen-specific CD8+ T cells expressing IL-2 and/or TNF-α and/or IFN-γ and/or CD40-L cytokines as determined by ICS. Determination of F4co was done by stimulating the F4 antigen with a peptide pool spanning (pool_F4co) or by adding individual frequencies of the CD8+ T cell response to each of the 4 antigens (F4co_est). (NCT00972725)
Timeframe: At Day 0, 7, 14, 30 and 180

Intervention	T cells/million cells (Median)																																			T cells/million cells (Median)
	F4co_est, CD40L+, D0	F4co_est, CD40L+, D7	F4co_est, CD40L+, D14	F4co_est, CD40L+, D30	F4co_est, CD40L+, D180	F4co_est, IL2+, D0	F4co_est, IL2+, D7	F4co_est, IL2+, D14	F4co_est, IL2+, D30	F4co_est, IL2+, D180	F4co_est, TNF+, D0	F4co_est, TNF+, D7	F4co_est, TNF+, D14	F4co_est, TNF+, D30	F4co_est, TNF+, D180	F4co_est, IFN+, D0	F4co_est, IFN+, D7	F4co_est, IFN+, D14	F4co_est, IFN+, D30	F4co_est, IFN+, D180	F4co_est, CD40L+IL2+, D0	F4co_est, CD40L+IL2+, D7	F4co_est, CD40L+IL2+, D14	F4co_est, CD40L+IL2+, D30	F4co_est, CD40L+IL2+, D180	F4co_est, CD40L+TNF+, D0	F4co_est, CD40L+TNF+, D7	F4co_est, CD40L+TNF+, D14	F4co_est, CD40L+TNF+, D30	F4co_est, CD40L+TNF+, D180	F4co_est, CD40L+IFN+, D0	F4co_est, CD40L+IFN+, D7	F4co_est, CD40L+IFN+, D14	F4co_est, CD40L+IFN+, D30	F4co_est, CD40L+IFN+, D180	F4co_est, IL2+TNF+, D0	F4co_est, IL2+TNF+, D7	F4co_est, IL2+TNF+, D14	F4co_est, IL2+TNF+, D30	F4co_est, IL2+TNF+, D180	F4co_est, IL2+IFN+, D0	F4co_est, IL2+IFN+, D7	F4co_est, IL2+IFN+, D14	F4co_est, IL2+IFN+, D30	F4co_est, IL2+IFN+, D180	F4co_est, TNF+IFN+, D0	F4co_est, TNF+IFN+, D7	F4co_est, TNF+IFN+, D14	F4co_est, TNF+IFN+, D30	F4co_est, TNF+IFN+, D180	F4co_est, CD40L+IL2+TNF+, D0	F4co_est, CD40L+IL2+TNF+, D7	F4co_est, CD40L+IL2+TNF+, D14	F4co_est, CD40L+IL2+TNF+, D30	F4co_est, CD40L+IL2+TNF+, D180	F4co_est, CD40L+IL2+IFN+, D0	F4co_est, CD40L+IL2+IFN+, D7	F4co_est, CD40L+IL2+IFN+, D14	F4co_est, CD40L+IL2+IFN+, D30	F4co_est, CD40L+IL2+IFN+, D180	F4co_est, CD40L+TNF+IFN+, D0	F4co_est, CD40L+TNF+IFN+, D7	F4co_est, CD40+TNF+IFN+, D14	F4co_est, CD40L+TNF+IFN+, D30	F4co_est, CD40L+TNF+IFN+, D180	F4co_est, IL2+TNF+IFN+, D0	F4co_est, IL2+TNF+IFN+, D7	F4co_est, IL2+TNF+IFN+, D14	F4co_est, IL2+TNF+IFN+, D30	F4co_est, IL2+TNF+IFN+, D180	F4co_est, CD40L+IL2+TNF+IFN+, D0	F4co_est, CD40L+IL2+TNF+IFN+, D7	F4co_est, CD40L+IL2+TNF+IFN+, D14	F4co_est, CD40L+IL2+TNF+IFN+, D30	F4co_est, CD40L+IL2+TNF+IFN+, D180
GSK732461 Group	301.00	532.00	201.00	242.00	150.00	64.00	84.00	141.00	73.00	127.50	9.50	176.00	4.00	67.00	14.50	58.50	29.00	21.00	22.00	23.50	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	5.00	4.00	4.00	4.00	28.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	23.00	4.00	27.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
GSK732461+Nivaquine Group	608.00	359.50	375.00	347.00	278.00	77.00	129.00	122.00	22.00	85.00	112.00	57.50	55.00	4.00	4.00	60.00	36.00	56.00	52.00	30.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	15.50	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00

Frequency of Antigen (Nef) Specific CD4+ T Cells Expressing at Least 2 Markers/ Cytokines

Intervention	T cells/million cells (Median)																																			T cells/million cells (Median)
	Nef, CD40L+, D0	Nef, CD40L+, D7	Nef, CD40L+, D14	Nef, CD40L+, D30	Nef, CD40L+, D180	Nef, IL2+, D0	Nef, IL2+, D7	Nef, IL2+, D14	Nef, IL2+, D30	Nef, IL2+, D180	Nef, TNF+, D0	Nef, TNF+, D7	Nef, TNF+, D14	Nef, TNF+, D30	Nef, TNF+, D180	Nef, IFN+, D0	Nef, IFN+, D7	Nef, IFN+, D14	Nef, IFN+, D30	Nef, IFN+, D180	Nef, CD40L+IL2+, D0	Nef, CD40L+IL2+, D7	Nef, CD40L+IL2+, D14	Nef, CD40L+IL2+, D30	Nef, CD40L+IL2+, D180	Nef, CD40L+TNF+, D0	Nef, CD40L+TNF+, D7	Nef, CD40L+TNF+, D14	Nef, CD40L+TNF+, D30	Nef, CD40L+TNF+, D180	Nef, CD40L+IFN+, D0	Nef, CD40L+IFN+, D7	Nef, CD40L+IFN+, D14	Nef, CD40L+IFN+, D30	Nef, CD40L+IFN+, D180	Nef, IL2+TNF+, D0	Nef, IL2+TNF+, D7	Nef, IL2+TNF+, D14	Nef, IL2+TNF+, D30	Nef, IL2+TNF+, D180	Nef, IL2+IFN+, D0	Nef, IL2+IFN+, D7	Nef, IL2+IFN+, D14	Nef, IL2+IFN+, D30	Nef, IL2+IFN+, D180	Nef, TNF+IFN+, D0	Nef, TNF+IFN+, D7	Nef, TNF+IFN+, D14	Nef, TNF+IFN+, D30	Nef, TNF+IFN+, D180	Nef, CD40L+IL2+TNF+, D0	Nef, CD40L+IL2+TNF+, D7	Nef, CD40L+IL2+TNF+, D14	Nef, CD40L+IL2+TNF+, D30	Nef, CD40L+IL2+TNF+, D180	Nef, CD40L+IL2+IFN+, D0	Nef, CD40L+IL2+IFN+, D7	Nef, CD40L+IL2+IFN+, D14	Nef, CD40L+IL2+IFN+, D30	Nef, CD40L+IL2+IFN+, D180	Nef, CD40L+TNF+IFN+, D0	Nef, CD40L+TNF+IFN+, D7	Nef, CD40+TNF+IFN+, D14	Nef, CD40L+TNF+IFN+, D30	Nef, CD40L+TNF+IFN+, D180	Nef, IL2+TNF+IFN+, D0	Nef, IL2+TNF+IFN+, D7	Nef, IL2+TNF+IFN+, D14	Nef, IL2+TNF+IFN+, D30	Nef, IL2+TNF+IFN+, D180	Nef, CD40L+IL2+TNF+IFN+, D0	Nef, CD40L+IL2+TNF+IFN+, D7	Nef, CD40L+IL2+TNF+IFN+, D14	Nef, CD40L+IL2+TNF+IFN+, D30	Nef, CD40L+IL2+TNF+IFN+, D180
GSK732461 Group	1.00	294.00	219.00	153.00	54.00	4.00	14.00	14.00	14.00	14.00	1.00	97.00	95.00	10.00	1.00	1.00	1.00	1.00	1.00	14.00	57.00	263.00	191.00	139.00	129.50	6.50	55.00	56.00	27.00	1.00	1.00	15.00	1.00	13.00	1.00	1.00	6.00	14.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	6.00	1.00	6.00	7.50	93.50	333.00	292.00	191.00	107.00	1.00	15.00	10.00	25.00	10.50	1.00	14.00	10.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	12.50	80.00	28.00	38.00	24.00
GSK732461+Nivaquine Group	113.00	339.00	224.00	193.00	107.00	1.00	29.50	25.00	1.00	21.00	1.00	115.00	28.00	1.00	1.00	1.00	14.00	20.00	1.00	14.00	84.00	199.00	258.00	97.00	148.00	3.00	102.50	95.00	56.00	13.00	1.00	14.00	14.00	1.00	1.00	9.00	14.00	28.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	5.00	4.00	1.00	1.00	97.00	268.50	480.00	401.00	118.00	1.00	33.00	8.00	14.00	14.00	1.00	12.50	14.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	14.00	67.50	29.00	41.00	26.00

Frequency of Antigen (Nef) Specific CD8+ T Cells Expressing at Least One Marker/ Cytokine

Intervention	T cells/million cells (Median)
	Nef, IL2+TNF+, D0	Nef, IL2+TNF+, D7	Nef, IL2+TNF+, D14	Nef, IL2+TNF+, D30	Nef, IL2+TNF+, D180	Nef, IL2+IFN+, D0	Nef, IL2+IFN+, D7	Nef, IL2+IFN+, D14	Nef, IL2+IFN+, D30	Nef, IL2+IFN+, D180	Nef, TNF+IFN+, D0	Nef, TNF+IFN+, D7	Nef, TNF+IFN+, D14	Nef, TNF+IFN+, D30	Nef, TNF+IFN+, D180	Nef, CD40L+IL2+TNF+, D0	Nef, CD40L+IL2+IL2+TNF+, D7	Nef, CD40L+IL2+TNF+, D14	Nef, CD40L+IL2+TNF+, D30	Nef, CD40L+IL2+TNF+, D180	Nef, CD40L+IL2+IFN+, D0	Nef, CD40L+IL2+IFN+, D7	Nef, CD40L+IL2+IFN+, D14	Nef, CD40L+IL2+IFN+, D30	Nef, CD40L+IL2+IFN+, D180	Nef, CD40L+TNF+IFN+, D0	Nef, CD40L+TNF+IFN+, D7	Nef, CD40+TNF+IFN+, D14	Nef, CD40L+TNF+IFN+, D30	Nef, CD40L+TNF+IFN+, D180	Nef, IL2+TNF+IFN+, D0	Nef, IL2+TNF+IFN+, D7	Nef, IL2+TNF+IFN+, D14	Nef, IL2+TNF+IFN+, D30	Nef, IL2+TNF+IFN+, D180	Nef, CD40L+IL2+TNF+IFN+, D0	Nef, CD40L+IL2+TNF+IFN+, D7	Nef, CD40L+IL2+TNF+IFN+, D14	Nef, CD40L+IL2+TNF+IFN+, D30	Nef, CD40L+IL2+TNF+IFN+, D180
GSK732461 Group	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
GSK732461+Nivaquine Group	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00

Frequency of Antigen (Nef) Specific CD8+ T Cells Expressing at Least One Marker/ Cytokine

Cytokine/marker co-expression profile was defined as the antigen-specific CD8+ T cells expressing IL-2 and/or TNF-α and/or IFN-γ and/or cluster of differentiation 40-ligand (CD40-L) cytokines as determined by ICS. (NCT00972725)
Timeframe: At Day 0, 7, 14, 30 and 180

Intervention	T cells/million cells (Median)
	Nef, CD40L+, D0	Nef, CD40L+, D7	Nef, CD40L+, D14	Nef, CD40L+, D30	Nef, CD40L+, D180	Nef, IL2+, D0	Nef, IL2+, D7	Nef, IL2+, D14	Nef, IL2+, D30	Nef, IL2+, D180	Nef, TNF+, D0	Nef, TNF+, D7	Nef, TNF+, D14	Nef, TNF+, D30	Nef, TNF+, D180	Nef, IFN+, D0	Nef, IFN+, D7	Nef, IFN+, D14	Nef, IFN+, D30	Nef, IFN+, D180	Nef, CD40L+IL2+, D0	Nef, CD40L+IL2+, D7	Nef, CD40L+IL2+, D14	Nef, CD40L+IL2+, D30	Nef, CD40L+IL2+, D180	Nef, CD40L+TNF+, D0	Nef, CD40L+TNF+, D7	Nef, CD40L+TNF+, D14	Nef, CD40L+TNF+, D30	Nef, CD40L+TNF+, D180	Nef, CD40L+IFN+, D0	Nef, CD40L+IFN+, D7	Nef, CD40L+IFN+, D14	Nef, CD40L+IFN+, D30	Nef, CD40L+IFN+, D180
GSK732461 Group	72.50	173.00	10.00	30.00	43.50	9.50	1.00	59.00	1.00	26.50	1.00	4.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
GSK732461+Nivaquine Group	155.00	90.50	122.00	191.00	134.00	1.00	22.00	40.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00

Frequency of Antigen (p17) Specific CD4+ T Cells Expressing at Least 2 Markers/ Cytokines

Intervention	T cells/million cells (Median)																																			T cells/million cells (Median)
	P17, CD40L+, D0	P17, CD40L+, D7	P17, CD40L+, D14	P17, CD40L+, D30	P17, CD40L+, D180	P17, IL2+, D0	P17, IL2+, D7	P17, IL2+, D14	P17, IL2+, D30	P17, IL2+, D180	P17, TNF+, D0	P17, TNF+, D7	P17, TNF+, D14	P17, TNF+, D30	P17, TNF+, D180	P17, IFN+, D0	P17, IFN+, D7	P17, IFN+, D14	P17, IFN+, D30	P17, IFN+, D180	P17, CD40L+IL2+, D0	P17, CD40L+IL2+, D7	P17, CD40L+IL2+, D14	P17, CD40L+IL2+, D30	P17, CD40L+IL2+, D180	P17, CD40L+TNF+, D0	P17, CD40L+TNF+, D7	P17, CD40L+TNF+, D14	P17, CD40L+TNF+, D30	P17, CD40L+TNF+, D180	P17, CD40L+IFN+, D0	P17, CD40L+IFN+, D7	P17, CD40L+IFN+, D14	P17, CD40L+IFN+, D30	P17, CD40L+IFN+, D180	P17, IL2+TNF+, D0	P17, IL2+TNF+, D7	P17, IL2+TNF+, D14	P17, IL2+TNF+, D30	P17, IL2+TNF+, D180	P17, IL2+IFN+, D0	P17, IL2+IFN+, D7	P17, IL2+IFN+, D14	P17, IL2+IFN+, D30	P17, IL2+IFN+, D180	P17, TNF+IFN+, D0	P17, TNF+IFN+, D7	P17, TNF+IFN+, D14	P17, TNF+IFN+, D30	P17, TNF+IFN+, D180	P17, CD40L+IL2+TNF+, D0	P17, CD40L+IL2+TNF+, D7	P17, CD40L+IL2+TNF+, D14	P17, CD40L+IL2+TNF+, D30	P17, CD40L+IL2+TNF+, D180	P17, CD40L+IL2+IFN+, D0	P17, CD40L+IL2+IFN+, D7	P17, CD40L+IL2+IFN+, D14	P17, CD40L+IL2+IFN+, D30	P17, CD40L+IL2+IFN+, D180	P17, CD40L+TNF+IFN+, D0	P17, CD40L+TNF+IFN+, D7	P17, CD40+TNF+IFN+, D14	P17, CD40L+TNF+IFN+, D30	P17, CD40L+TNF+IFN+, D180	P17, IL2+TNF+IFN+, D0	P17, IL2+TNF+IFN+, D7	P17, IL2+TNF+IFN+, D14	P17, IL2+TNF+IFN+, D30	P17, IL2+TNF+IFN+, D180	P17, CD40L+IL2+TNF+IFN+, D0	P17, CD40L+IL2+TNF+IFN+, D7	P17, CD40L+IL2+TNF+IFN+, D14	P17, CD40L+IL2+TNF+IFN+, D30	P17, CD40L+IL2+TNF+IFN+, D180
GSK732461 Group	23.50	217.00	132.00	82.00	78.50	1.00	5.00	1.00	14.00	1.00	1.00	68.00	140.00	82.00	20.00	1.00	14.00	9.00	1.00	1.00	69.00	165.00	139.00	110.00	193.00	1.00	61.00	41.00	14.00	1.00	1.00	14.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	115.00	302.00	314.00	203.00	239.50	1.00	14.00	1.00	14.00	13.00	1.00	14.00	11.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	31.00	42.00	55.00	17.50
GSK732461+Nivaquine Group	1.00	237.50	112.00	150.00	28.00	1.00	28.00	8.00	1.00	1.00	1.00	40.00	67.00	14.00	1.00	1.00	1.00	1.00	1.00	14.00	27.00	196.00	112.00	122.00	138.00	24.00	41.00	28.00	41.00	14.00	1.00	7.50	8.00	10.00	1.00	1.00	1.00	10.00	1.00	4.00	1.00	1.00	1.00	1.00	1.00	1.00	7.00	1.00	1.00	1.00	84.00	194.00	192.00	204.00	94.00	1.00	27.50	1.00	10.00	13.00	1.00	5.00	1.00	1.00	1.00	1.00	4.00	1.00	1.00	1.00	1.00	34.50	23.00	40.00	14.00

Frequency of Antigen (p17) Specific CD8+ T Cells Expressing at Least One Marker/ Cytokine

Intervention	T cells/million cells (Median)																																			T cells/million cells (Median)
	P17, CD40L+, D0	P17, CD40L+, D7	P17, CD40L+, D14	P17, CD40L+, D30	P17, CD40L+, D180	P17, IL2+, D0	P17, IL2+, D7	P17, IL2+, D14	P17, IL2+, D30	P17, IL2+, D180	P17, TNF+, D0	P17, TNF+, D7	P17, TNF+, D14	P17, TNF+, D30	P17, TNF+, D180	P17, IFN+, D0	P17, IFN+, D7	P17, IFN+, D14	P17, IFN+, D30	P17, IFN+, D180	P17, CD40L+IL2+, D0	P17, CD40L+IL2+, D7	P17, CD40L+IL2+, D14	P17, CD40L+IL2+, D30	P17, CD40L+IL2+, D180	P17, CD40L+TNF+, D0	P17, CD40L+TNF+, D7	P17, CD40L+TNF+, D14	P17, CD40L+TNF+, D30	P17, CD40L+TNF+, D180	P17, CD40L+IFN+, D0	P17, CD40L+IFN+, D7	P17, CD40L+IFN+, D14	P17, CD40L+IFN+, D30	P17, CD40L+IFN+, D180	P17, IL2+TNF+, D0	P17, IL2+TNF+, D7	P17, IL2+TNF+, D14	P17, IL2+TNF+, D30	P17, IL2+TNF+, D180	P17, IL2+IFN+, D0	P17, IL2+IFN+, D7	P17, IL2+IFN+, D14	P17, IL2+IFN+, D30	P17, IL2+IFN+, D180	P17, TNF+IFN+, D0	P17, TNF+IFN+, D7	P17, TNF+IFN+, D14	P17, TNF+IFN+, D30	P17, TNF+IFN+, D180	P17, CD40L+IL2+TNF+, D0	P17, CD40L+IL2+TNF+, D7	P17, CD40L+IL2+TNF+, D14	P17, CD40L+IL2+TNF+, D30	P17, CD40L+IL2+TNF+, D180	P17, CD40L+IL2+IFN+, D0	P17, CD40L+IL2+IFN+, D7	P17, CD40L+IL2+IFN+, D14	P17, CD40L+IL2+IFN+, D30	P17, CD40L+IL2+IFN+, D180	P17, CD40L+TNF+IFN+, D0	P17, CD40L+TNF+IFN+, D7	P17, CD40+TNF+IFN+, D14	P17, CD40L+TNF+IFN+, D30	P17, CD40L+TNF+IFN+, D180	P17, IL2+TNF+IFN+, D0	P17, IL2+TNF+IFN+, D7	P17, IL2+TNF+IFN+, D14	P17, IL2+TNF+IFN+, D30	P17, IL2+TNF+IFN+, D180	p17, CD40L+IL2+TNF+IFN+, D0	P17, CD40L+IL2+TNF+IFN+, D7	P17, CD40L+IL2+TNF+IFN+, D14	P17, CD40L+IL2+TNF+IFN+, D30	P17, CD40L+IL2+TNF+IFN+, D180
GSK732461 Group	1.00	34.00	1.00	13.00	4.50	1.00	21.00	33.00	1.00	39.00	1.00	21.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
GSK732461+Nivaquine Group	65.00	40.50	1.00	7.00	44.00	1.00	7.50	25.00	1.00	10.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00

Frequency of Antigen (p24) Specific CD4+ T Cells Expressing at Least 2 Markers/ Cytokines

Intervention	T cells/million cells (Median)																																			T cells/million cells (Median)
	P24, CD40L+, D0	P24, CD40L+, D7	P24, CD40L+, D14	P24, CD40L+, D30	P24, CD40L+, D180	P24, IL2+, D0	P24, IL2+, D7	P24, IL2+, D14	P24, IL2+, D30	P24, IL2+, D180	P24, TNF+, D0	P24, TNF+, D7	P24, TNF+, D14	P24, TNF+, D30	P24, TNF+, D180	P24, IFN+, D0	P24, IFN+, D7	P24, IFN+, D14	P24, IFN+, D30	P24, IFN+, D180	P24, CD40L+IL2+, D0	P24, CD40L+IL2+, D7	P24, CD40L+IL2+, D14	P24, CD40L+IL2+, D30	P24, CD40L+IL2+, D180	P24, CD40L+TNF+, D0	P24, CD40L+TNF+, D7	P24, CD40L+TNF+, D14	P24, CD40L+TNF+, D30	P24, CD40L+TNF+, D180	P24, CD40L+IFN+, D0	P24, CD40L+IFN+, D7	P24, CD40L+IFN+, D14	P24, CD40L+IFN+, D30	P24, CD40L+IFN+, D180	P24, IL2+TNF+, D0	P24, IL2+TNF+, D7	P24, IL2+TNF+, D14	P24, IL2+TNF+, D30	P24, IL2+TNF+, D180	P24, IL2+IFN+, D0	P24, IL2+IFN+, D7	P24, IL2+IFN+, D14	P24, IL2+IFN+, D30	P24, IL2+IFN+, D180	P24, TNF+IFN+, D0	P24, TNF+IFN+, D7	P24, TNF+IFN+, D14	P24, TNF+IFN+, D30	P24, TNF+IFN+, D180	P24, CD40L+IL2+TNF+, D0	P24, CD40L+IL2+TNF+, D7	P24, CD40L+IL2+TNF+, D14	P24, CD40L+IL2+TNF+, D30	P24, CD40L+IL2+TNF+, D180	P24, CD40L+IL2+IFN+, D0	P24, CD40L+IL2+IFN+, D7	P24, CD40L+IL2+IFN+, D14	P24, CD40L+IL2+IFN+, D30	P24, CD40L+IL2+IFN+, D180	P24, CD40L+TNF+IFN+, D0	P24, CD40L+TNF+IFN+, D7	P24, CD40+TNF+IFN+, D14	P24, CD40L+TNF+IFN+, D30	P24, CD40L+TNF+IFN+, D180	P24, IL2+TNF+IFN+, D0	P24, IL2+TNF+IFN+, D7	P24, IL2+TNF+IFN+, D14	P24, IL2+TNF+IFN+, D30	P24, IL2+TNF+IFN+, D180	P24, CD40L+IL2+TNF+IFN+, D0	P24, CD40L+IL2+TNF+IFN+, D7	P24, CD40L+IL2+TNF+IFN+, D14	P24, CD40L+IL2+TNF+IFN+, D30	P24, CD40L+IL2+TNF+IFN+, D180
GSK732461 Group	70.00	395.00	154.00	181.00	165.00	13.00	24.00	5.00	41.00	2.50	6.00	73.00	53.00	8.00	1.00	1.00	14.00	14.00	1.00	1.00	137.00	230.00	284.00	189.00	196.00	21.00	99.00	125.00	42.00	14.50	1.00	1.00	9.00	1.00	1.00	1.00	9.00	22.00	14.00	27.00	1.00	1.00	1.00	1.00	1.00	1.00	12.00	1.00	14.00	1.00	135.50	410.00	456.00	379.00	229.50	9.50	14.00	23.00	15.00	14.00	1.00	14.00	14.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	14.50	70.00	81.00	57.00	22.50
GSK732461+Nivaquine Group	79.00	452.00	217.00	86.00	118.00	1.00	40.50	14.00	14.00	35.00	1.00	69.00	36.00	1.00	35.00	1.00	4.00	1.00	1.00	14.00	176.00	275.00	244.00	83.00	234.00	14.00	104.00	86.00	54.00	1.00	1.00	12.50	11.00	1.00	1.00	1.00	16.50	27.00	1.00	14.00	1.00	1.00	1.00	1.00	1.00	1.00	7.50	1.00	1.00	1.00	267.00	389.50	569.00	516.00	233.00	1.00	20.50	11.00	1.00	18.00	1.00	12.50	14.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	140.50	66.00	40.00	43.00

Frequency of Antigen (p24) Specific CD8+ T Cells Expressing at Least One Marker/ Cytokine

Intervention	T cells/million cells (Median)																																			T cells/million cells (Median)
	P24, CD40L+, D0	P24, CD40L+, D7	P24, CD40L+, D14	P24, CD40L+, D30	P24, CD40L+, D180	P24, IL2+, D0	P24, IL2+, D7	P24, IL2+, D14	P24, IL2+, D30	P24, IL2+, D180	P24, TNF+, D0	P24, TNF+, D7	P24, TNF+, D14	P24, TNF+, D30	P24, TNF+, D180	P24, IFN+, D0	P24, IFN+, D7	P24, IFN+, D14	P24, IFN+, D30	P24, IFN+, D180	P24, CD40L+IL2+, D0	P24, CD40L+IL2+, D7	P24, CD40L+IL2+, D14	P24, CD40L+IL2+, D30	P24, CD40L+IL2+, D180	P24, CD40L+TNF+, D0	P24, CD40L+TNF+, D7	P24, CD40L+TNF+, D14	P24, CD40L+TNF+, D30	P24, CD40L+TNF+, D180	P24, CD40L+IFN+, D0	P24, CD40L+IFN+, D7	P24, CD40L+IFN+, D14	P24, CD40L+IFN+, D30	P24, CD40L+IFN+, D180	P24, IL2+TNF+, D0	P24, IL2+TNF+, D7	P24, IL2+TNF+, D14	P24, IL2+TNF+, D30	P24, IL2+TNF+, D180	P24, IL2+IFN+, D0	P24, IL2+IFN+, D7	P24, IL2+IFN+, D14	P24, IL2+IFN+, D30	P24, IL2+IFN+, D180	P24, TNF+IFN+, D0	P24, TNF+IFN+, D7	P24, TNF+IFN+, D14	P24, TNF+IFN+, D30	P24, TNF+IFN+, D180	P24, CD40L+IL2+TNF+, D0	P24, CD40L+IL2+TNF+, D7	P24, CD40L+IL2+TNF+, D14	P24, CD40L+IL2+TNF+, D30	P24, CD40L+IL2+TNF+, D180	P24, CD40L+IL2+IFN+, D0	P24, CD40L+IL2+IFN+, D7	P24, CD40L+IL2+IFN+, D14	P24, CD40L+IL2+IFN+, D30	P24, CD40L+IL2+IFN+, D180	P24, CD40L+TNF+IFN+, D0	P24, CD40L+TNF+IFN+, D7	P24, CD40+TNF+IFN+, D14	P24, CD40L+TNF+IFN+, D30	P24, CD40L+TNF+IFN+, D180	P24, IL2+TNF+IFN+, D0	P24, IL2+TNF+IFN+, D7	P24, IL2+TNF+IFN+, D14	P24, IL2+TNF+IFN+, D30	P24, IL2+TNF+IFN+, D180	P24, CD40L+IL2+TNF+IFN+, D0	P24, CD40L+IL2+TNF+IFN+, D7	P24, CD40L+IL2+TNF+IFN+, D14	P24, CD40L+IL2+TNF+IFN+, D30	P24, CD40L+IL2+TNF+IFN+, D180
GSK732461 Group	103.50	37.00	30.00	59.00	1.00	1.00	1.00	1.00	32.00	1.00	1.00	27.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
GSK732461+Nivaquine Group	178.00	61.50	100.00	1.00	16.00	1.00	7.50	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	5.00	1.00	1.00	25.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00

Frequency of Antigen (pool_F4co) Specific CD4+ T Cells Expressing at Least 2 Markers/ Cytokines

Intervention	T cells/million cells (Median)
	Pool_F4co, CD40L+, D0	Pool_F4co, CD40L+, D7	Pool_F4co, CD40L+, D14	Pool_F4co, CD40L+, D30	Pool_F4co, CD40L+, D180	Pool_F4co, IL2+, D0	Pool_F4co, IL2+, D7	Pool_F4co, IL2+, D14	Pool_F4co, IL2+, D30	Pool_F4co, IL2+, D180	Pool_F4co, TNF+, D0	Pool_F4co, TNF+, D7	Pool_F4co, TNF+, D14	Pool_F4co, TNF+, D30	Pool_F4co, TNF+, D180	Pool_F4co, IFN+, D0	Pool_F4co, IFN+, D7	Pool_F4co, IFN+, D14	Pool_F4co, IFN+, D30	Pool_F4co, IFN+, D180	Pool_F4co, CD40L+IL2+, D0	Pool_F4co, CD40L+IL2+, D7	Pool_F4co, CD40L+IL2+, D14	Pool_F4co, CD40L+IL2+, D30	Pool_F4co, CD40L+IL2+, D180	Pool_F4co, CD40L+TNF+, D0	Pool_F4co, CD40L+TNF+, D7	Pool_F4co, CD40L+TNF+, D14	Pool_F4co, CD40L+TNF+, D30	Pool_F4co, CD40L+TNF+, D180	Pool_F4co, CD40L+IFN+, D0	Pool_F4co, CD40L+IFN+, D7	Pool_F4co, CD40L+IFN+, D14	Pool_F4co, CD40L+IFN+, D30	Pool_F4co, CD40L+IFN+, D180
GSK732461 Group	264.50	2215.00	1175.00	650.00	429.00	57.00	81.00	92.00	97.00	58.50	242.50	625.00	610.00	445.00	56.50	1.00	98.00	47.00	38.00	38.50	568.50	2199.00	2037.00	1277.00	1351.50	69.50	575.00	498.00	291.00	74.00	1.00	112.00	56.00	41.00	27.00
GSK732461+Nivaquine Group	177.00	1809.50	1015.00	653.00	497.00	41.00	141.50	100.00	55.00	32.00	20.00	547.50	612.00	225.00	126.00	7.00	110.00	32.00	14.00	35.00	469.00	1542.50	1423.00	964.00	961.00	102.00	514.50	706.00	399.00	81.00	1.00	82.50	59.00	21.00	14.00

Frequency of Antigen (pool_F4co) Specific CD4+ T Cells Expressing at Least 2 Markers/Cytokines

Intervention	T cells/million cells (Median)
	Pool_F4co, IL2+TNF+, D0	Pool_F4co, IL2+TNF+, D7	Pool_F4co, IL2+TNF+, D14	Pool_F4co, IL2+TNF+, D30	Pool_F4co, IL2+TNF+, D180	Pool_F4co, IL2+IFN+, D0	Pool_F4co, IL2+IFN+, D7	Pool_F4co, IL2+IFN+, D14	Pool_F4co, IL2+IFN+, D30	Pool_F4co, IL2+IFN+, D180	Pool_F4co, TNF+IFN+, D0	Pool_F4co, TNF+IFN+, D7	Pool_F4co, TNF+IFN+, D14	Pool_F4co, TNF+IFN+, D30	Pool_F4co, TNF+IFN+, D180	Pool_F4co, CD40L+IL2+TNF+, D0	Pool_F4co, CD40L+IL2+TNF+, D7	Pool_F4co, CD40L+IL2+TNF+, D14	Pool_F4co, CD40L+IL2+TNF+, D30	Pool_F4co, CD40L+IL2+TNF+, D180	Pool_F4co, CD40L+IL2+IFN+, D0	Pool_F4co, CD40L+IL2+IFN+, D7	Pool_F4co, CD40L+IL2+IFN+, D14	Pool_F4co, CD40L+IL2+IFN+, D30	Pool_F4co, CD40L+IL2+IFN+, D180	Pool_F4co, CD40L+TNF+IFN+, D0	Pool_F4co, CD40L+TNF+IFN+, D7	Pool_F4co, CD40+TNF+IFN+, D14	Pool_F4co, CD40L+TNF+IFN+, D30	Pool_F4co, CD40L+TNF+IFN+, D180	Pool_F4co, IL2+TNF+IFN+, D0	Pool_F4co, IL2+TNF+IFN+, D7	Pool_F4co, IL2+TNF+IFN+, D14	Pool_F4co, IL2+TNF+IFN+, D30	Pool_F4co, IL2+TNF+IFN+, D180	Pool_F4co, CD40L+IL2+TNF+IFN+, D0	Pool_F4co, CD40L+IL2+TNF+IFN+, D7	Pool_F4co, CD40L+IL2+TNF+IFN+, D14	Pool_F4co, CD40L+IL2+TNF+IFN+, D30	Pool_F4co, CD40L+IL2+TNF+IFN+, D180
GSK732461 Group	56.00	93.00	83.00	109.00	59.50	1.00	1.00	1.00	11.00	14.00	1.00	56.00	83.00	75.00	28.00	836.00	2764.00	2804.00	2137.00	1246.00	30.50	204.00	151.00	109.00	60.50	1.00	97.00	85.00	82.00	27.00	11.00	14.00	14.00	17.00	17.50	147.00	484.00	639.00	413.00	216.00
GSK732461+Nivaquine Group	55.00	160.00	122.00	25.00	26.00	1.00	6.00	1.00	1.00	14.00	1.00	38.00	51.00	27.00	19.00	792.00	1430.00	2032.00	2243.00	1146.00	28.00	140.00	96.00	24.00	116.00	1.00	70.00	74.00	55.00	27.00	1.00	18.50	8.00	1.00	13.00	95.00	285.50	337.00	244.00	163.00

Frequency of Antigen (pool_F4co) Specific CD8+ T Cells Expressing at Least One Marker/ Cytokine

Intervention	T cells/million cells (Median)																																			T cells/million cells (Median)
	Pool_F4co, CD40L+, D0	Pool_F4co, CD40L+, D7	Pool_F4co, CD40L+, D14	Pool_F4co, CD40L+, D30	Pool_F4co, CD40L+, D180	Pool_F4co, IL2+, D0	Pool_F4co, IL2+, D7	Pool_F4co, IL2+, D14	Pool_F4co, IL2+, D30	Pool_F4co, IL2+, D180	Pool_F4co, TNF+, D0 ]	Pool_F4co, TNF+, D7	Pool_F4co, TNF+, D14	Pool_F4co, TNF+, D30	Pool_F4co, TNF+, D180	Pool_F4co, IFN+, D0	Pool_F4co, IFN+, D7	Pool_F4co, IFN+, D14	Pool_F4co, IFN+, D30	Pool_F4co, IFN+, D180	Pool_F4co, CD40L+IL2+, D0	Pool_F4co, CD40L+IL2+, D7	Pool_F4co, CD40L+IL2+, D14	Pool_F4co, CD40L+IL2+, D30	Pool_F4co, CD40L+IL2+, D180	Pool_F4co, CD40L+TNF+, D0	Pool_F4co, CD40L+TNF+, D7	Pool_F4co, CD40L+TNF+, D14	Pool_F4co, CD40L+TNF+, D30	Pool_F4co, CD40L+TNF+, D180	Pool_F4co, CD40L+IFN+, D0	Pool_F4co, CD40L+IFN+, D7	Pool_F4co, CD40L+IFN+, D14	Pool_F4co, CD40L+IFN+, D30	Pool_F4co, CD40L+IFN+, D180	Pool_F4co, IL2+TNF+, D0	Pool_F4co, IL2+TNF+, D7	Pool_F4co, IL2+TNF+, D14	Pool_F4co, IL2+TNF+, D30	Pool_F4co, IL2+TNF+, D180	Pool_F4co, IL2+IFN+, D0	Pool_F4co, IL2+IFN+, D7	Pool_F4co, IL2+IFN+, D14	Pool_F4co, IL2+IFN+, D30	Pool_F4co, IL2+IFN+, D180	Pool_F4co, TNF+IFN+, D0	Pool_F4co, TNF+IFN+, D7	Pool_F4co, TNF+IFN+, D14	Pool_F4co, TNF+IFN+, D30	Pool_F4co, TNF+IFN+, D180	Pool_F4co, CD40L+IL2+TNF+, D0	Pool_F4co, CD40L+IL2+TNF+, D7	Pool_F4co, CD40L+IL2+TNF+, D14	Pool_F4co, CD40L+IL2+TNF+, D30	Pool_F4co, CD40L+IL2+TNF+, D180	Pool_F4co, CD40L+IL2+IFN+, D0	Pool_F4co, CD40L+IL2+IFN+, D7	Pool_F4co, CD40L+IL2+IFN+, D14	Pool_F4co, CD40L+IL2+IFN+, D30	Pool_F4co, CD40L+IL2+IFN+, D180	Pool_F4co, CD40L+TNF+IFN+, D0	Pool_F4co, CD40L+TNF+IFN+, D7	Pool_F4co, CD40+TNF+IFN+, D14	Pool_F4co, CD40L+TNF+IFN+, D30	Pool_F4co, CD40L+TNF+IFN+, D180	Pool_F4co, IL2+TNF+IFN+, D0	Pool_F4co, IL2+TNF+IFN+, D7	Pool_F4co, IL2+TNF+IFN+, D14	Pool_F4co, IL2+TNF+IFN+, D30	Pool_F4co, IL2+TNF+IFN+, D180 [	Pool_F4co, CD40L+IL2+TNF+IFN+, D0	Pool_F4co, CD40L+IL2+TNF+IFN+, D7	Pool_F4co, CD40L+IL2+TNF+IFN+, D14	Pool_F4co, CD40L+IL2+TNF+IFN+, D30	Pool_F4co, CD40L+IL2+TNF+IFN+, D180
GSK732461 Group	105.00	185.00	1.00	69.00	48.00	22.00	3.00	32.00	20.00	1.00	1.00	5.00	1.00	1.00	1.00	28.00	14.00	1.00	17.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
GSK732461+Nivaquine Group	114.00	141.50	113.00	84.00	61.00	1.00	26.00	31.00	1.00	27.00	1.00	1.00	2.00	1.00	1.00	1.00	1.00	5.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00

Frequency of Antigen (RT) Specific CD4+ T Cells Expressing at Least 2 Markers/ Cytokines

Intervention	T cells/million cells (Median)																																			T cells/million cells (Median)
	RT, CD40L+, D0	RT, CD40L+, D7	RT, CD40L+, D14	RT, CD40L+, D30	RT, CD40L+, D180	RT, IL2+, D0	RT, IL2+, D7	RT, IL2+, D14	RT, IL2+, D30	RT, IL2+, D180	RT, TNF+, D0	RT, TNF+, D7	RT, TNF+, D14	RT, TNF+, D30	RT, TNF+, D180	RT, IFN+, D0	RT, IFN+, D7	RT, IFN+, D14	RT, IFN+, D30	RT, IFN+, D180	RT, CD40L+IL2+, D0	RT, CD40L+IL2+, D7	RT, CD40L+IL2+, D14	RT, CD40L+IL2+, D30	RT, CD40L+IL2+, D180	RT, CD40L+TNF+, D0	RT, CD40L+TNF+, D7	RT, CD40L+TNF+, D14	RT, CD40L+TNF+, D30	RT, CD40L+TNF+, D180	RT, CD40L+IFN+, D0	RT, CD40L+IFN+, D7	RT, CD40L+IFN+, D14	RT, CD40L+IFN+, D30	RT, CD40L+IFN+, D180	RT, IL2+TNF+, D0	RT, IL2+TNF+, D7	RT, IL2+TNF+, D14	RT, IL2+TNF+, D30	RT, IL2+TNF+, D180	RT, IL2+IFN+, D0	RT, IL2+IFN+, D7	RT, IL2+IFN+, D14	RT, IL2+IFN+, D30	RT, IL2+IFN+, D180	RT, TNF+IFN+, D0	RT, TNF+IFN+, D7	RT, TNF+IFN+, D14	RT, TNF+IFN+, D30	RT, TNF+IFN+, D180	RT, CD40L+IL2+TNF+, D0	RT, CD40L+IL2+TNF+, D7	RT, CD40L+IL2+TNF+, D14	RT, CD40L+IL2+TNF+, D30	RT, CD40L+IL2+TNF+, D180	RT, CD40L+IL2+IFN+, D0	RT, CD40L+IL2+IFN+, D7	RT, CD40L+IL2+IFN+, D14	RT, CD40L+IL2+IFN+, D30	RT, CD40L+IL2+IFN+, D180	RT, CD40L+TNF+IFN+, D0	RT, CD40L+TNF+IFN+, D7	RT, CD40+TNF+IFN+, D14	RT, CD40L+TNF+IFN+, D30	RT, CD40L+TNF+IFN+, D180	RT, IL2+TNF+IFN+, D0	RT, IL2+TNF+IFN+, D7	RT, IL2+TNF+IFN+, D14	RT, IL2+TNF+IFN+, D30	RT, IL2+TNF+IFN+, D180	RT, CD40L+IL2+TNF+IFN+, D0	RT, CD40L+IL2+TNF+IFN+, D7	RT, CD40L+IL2+TNF+IFN+, D14	RT, CD40L+IL2+TNF+IFN+, D30	RT, CD40L+IL2+TNF+IFN+, D180
GSK732461 Group	184.00	1209.00	748.00	309.00	249.00	15.00	42.00	35.00	36.00	74.00	61.50	312.00	318.00	231.00	7.00	13.00	56.00	16.00	1.00	12.50	315.00	1424.00	990.00	828.00	797.50	36.50	315.00	291.00	137.00	40.50	1.00	84.00	28.00	15.00	14.00	6.50	37.00	22.00	55.00	67.50	1.00	1.00	1.00	1.00	1.00	1.00	28.00	14.00	19.00	15.00	474.50	1575.00	1901.00	1297.00	709.50	12.50	151.00	84.00	56.00	40.50	1.00	56.00	28.00	15.00	1.00	1.00	14.00	1.00	13.00	13.50	48.00	213.00	285.00	237.00	87.50
GSK732461+Nivaquine Group	163.00	1080.50	522.00	262.00	229.00	1.00	85.50	97.00	24.00	41.00	18.00	421.00	228.00	124.00	74.00	7.00	91.50	9.00	1.00	13.00	377.00	924.00	922.00	615.00	558.00	41.00	237.00	300.00	204.00	54.00	1.00	69.00	27.00	14.00	1.00	14.00	83.50	53.00	27.00	26.00	1.00	10.50	1.00	1.00	1.00	1.00	18.00	23.00	14.00	1.00	475.00	842.00	1606.00	1209.00	471.00	15.00	89.50	54.00	30.00	68.00	1.00	43.00	50.00	27.00	1.00	1.00	13.50	8.00	1.00	1.00	57.00	206.50	254.00	136.00	64.00

Frequency of Antigen (RT) Specific CD8+ T Cells Expressing at Least One Marker/ Cytokine

Intervention	T cells/million cells (Median)
	RT, IL2+TNF+, D0	RT, IL2+TNF+, D7	RT, IL2+TNF+, D14	RT, IL2+TNF+, D30	RT, IL2+TNF+, D180	RT, IL2+IFN+, D0	RT, IL2+IFN+, D7	RT, IL2+IFN+, D14	RT, IL2+IFN+, D30	RT, IL2+IFN+, D180	RT, TNF+IFN+, D0	RT, TNF+IFN+, D7	RT, TNF+IFN+, D14	RT, TNF+IFN+, D30	RT, TNF+IFN+, D180	RT, CD40L+IL2+TNF+, D0	RT, CD40L+IL2+TNF+, D7	RT, CD40L+IL2+TNF+, D14	RT, CD40L+IL2+TNF+, D30	RT, CD40L+IL2+TNF+, D180	RT, CD40L+IL2+IFN+, D0	RT, CD40L+IL2+IFN+, D7	RT, CD40L+IL2+IFN+, D14	RT, CD40L+IL2+IFN+, D30	RT, CD40L+IL2+IFN+, D180	RT, CD40L+TNF+IFN+, D0	RT, CD40L+TNF+IFN+, D7	RT, CD40+TNF+IFN+, D14	RT, CD40L+TNF+IFN+, D30	RT, CD40L+TNF+IFN+, D180	RT, IL2+TNF+IFN+, D0	RT, IL2+TNF+IFN+, D7	RT, IL2+TNF+IFN+, D14	RT, IL2+TNF+IFN+, D30	RT, IL2+TNF+IFN+, D180	RT, CD40L+IL2+TNF+IFN+, D0	RT, CD40L+IL2+TNF+IFN+, D7	RT, CD40L+IL2+TNF+IFN+, D14	RT, CD40L+IL2+TNF+IFN+, D30	RT, CD40L+IL2+TNF+IFN+, D180
GSK732461 Group	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
GSK732461+Nivaquine Group	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00

Frequency of Antigen (RT) Specific CD8+ T Cells Expressing at Least One Marker/ Cytokine

Intervention	T cells/million cells (Median)
	RT, CD40L+, D0	RT, CD40L+, D7	RT, CD40L+, D14	RT, CD40L+, D30	RT, CD40L+, D180	RT, IL2+, D0	RT, IL2+, D7	RT, IL2+, D14	RT, IL2+, D30	RT, IL2+, D180	RT, TNF+, D0	RT, TNF+, D7	RT, TNF+, D14	RT, TNF+, D30	RT, TNF+, D180,	RT, IFN+, D0	RT, IFN+, D7	RT, IFN+, D14	RT, IFN+, D30	RT, IFN+, D180	RT, CD40L+IL2+, D0	RT, CD40L+IL2+, D7	RT, CD40L+IL2+, D14	RT, CD40L+IL2+, D30	RT, CD40L+IL2+, D180	RT, CD40L+TNF+, D0	RT, CD40L+TNF+, D7	RT, CD40L+TNF+, D14	RT, CD40L+TNF+, D30	RT, CD40L+TNF+, D180	RT, CD40L+IFN+, D0	RT, CD40L+IFN+, D7	RT, CD40L+IFN+, D14	RT, CD40L+IFN+, D30	RT, CD40L+IFN+, D180
GSK732461 Group	123.00	168.00	1.00	27.00	52.50	1.00	1.00	32.00	1.00	1.00	1.00	34.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
GSK732461+Nivaquine Group	146.00	121.50	91.00	113.00	1.00	31.00	32.50	64.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	14.00	4.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00

Levels of Haematological and Biochemical Parameters

Among haematological and biochemical parameters determined were alanine aminotransferase [ALT], aspartate aminotransferase [ASA], basophils [BASO], creatinine [CREA], eosinophils [EOS], haematocrit [HAEM], haemoglobin [HAEMO], lymphocytes [LYMPH], monocytes [MONO], neutrophils [NEU], platelets [PLA], red blood cells [RBC], urea [UR] and white blood cells [WBC]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - unknown, below, within and above. (NCT00972725)
Timeframe: At Day 0

Intervention	Participants (Count of Participants)
	ALT, Unknown	ALT, Below	ALT, Within	ALT, Above	ASA, Unknown	ASA, Below	ASA, Within	ASA, Above	BASO, Unknown	BASO, Below	BASO, Within	BASO, Above	CREA, Unknown	CREA, Below	CREA, Within	CREA, Above	EOS, Unknown	EOS, Below	EOS, Within	EOS, Above	HAEM, Unknown	HAEM, Below	HAEM, Within	HAEM, Above	HAEMO, Unknown	HAEMO, Below	HAEMO, Within	HAEMO, Above	LYMPH, Unknown	LYMPH, Below	LYMPH, Within	LYMPH, Above	MONO, Unknown	MONO, Below	MONO, Within	MONO, Above	NEU, Unknown	NEU, Below	NEU, Within	NEU, Above	PLA, Unknown	PLA, Below	PLA, Within	PLA, Above	RBC, Unknown	RBC, Below	RBC, Within	RBC, Above	UR, Unknown	UR, Below	UR, Within	UR, Above	WBC, Unknown	WBC, Below	WBC, Within	WBC, Above
GSK732461 Group	0	0	15	0	0	0	15	0	0	4	11	0	0	0	14	1	0	1	14	0	0	0	15	0	0	0	15	0	0	3	12	0	0	0	14	1	0	0	13	2	0	0	14	1	0	0	15	0	0	0	15	0	0	0	13	2
GSK732461+Nivaquine Group	0	0	13	0	0	0	13	0	0	3	10	0	0	0	12	1	0	1	12	0	0	1	12	0	0	0	12	1	0	1	12	0	0	0	13	0	0	2	11	0	0	0	13	0	0	0	13	0	0	0	13	0	0	0	13	0

Levels of Haematological and Biochemical Parameters

Intervention	Participants (Count of Participants)
	ALT, Unknown	ALT, Below	ALT, Within	ALT, Above	ASA, Unknown	ASA, Below	ASA, Within	ASA, Above	BASO, Unknown	BASO, Below	BASO, Within	BASO, Above	CREA, Unknown	CREA, Below	CREA, Within	CREA, Above	EOS, Unknown	EOS, Below	EOS, Within	EOS, Above	HAEM, Unknown	HAEM, Below	HAEM, Within	HAEM, Above	HAEMO, Unknown	HAEMO, Below	HAEMO, Within	HAEMO, Above	LYMPH, Unknown	LYMPH, Below	LYMPH, Within	LYMPH, Above	MONO, Unknown	MONO, Below	MONO, Within	MONO, Above	NEU, Unknown	NEU, Below	NEU, Within	NEU, Above	PLA, Unknown	PLA, Below	PLA, Within	PLA, Above	RBC, Unknown	RBC, Below	RBC, Within	RBC, Above	UR, Unknown	UR, Below	UR, Within	UR, Above	WBC, Unknown	WBC, Below	WBC, Within	WBC, Above
GSK732461 Group	0	0	15	0	0	0	15	0	0	2	13	0	0	0	15	0	0	0	14	1	0	0	15	0	0	0	15	0	0	3	12	0	0	0	14	1	0	1	14	0	0	0	14	1	0	0	15	0	0	0	15	0	0	0	15	0
GSK732461+Nivaquine Group	0	0	13	0	0	0	13	0	0	1	12	0	0	0	13	0	0	1	11	1	0	0	13	0	0	0	13	0	0	1	11	1	0	0	13	0	0	2	10	1	0	0	13	0	0	0	13	0	0	0	13	0	0	0	12	1

Levels of Haematological and Biochemical Parameters

Intervention	Participants (Count of Participants)
	ALT, Unknown	ALT, Below	ALT, Within	ALT, Above	ASA, Unknown	ASA, Below	ASA, Within	ASA, Above	BASO, Unknown	BASO, Below	BASO, Within	BASO, Above	CREA, Unknown	CREA, Below	CREA, Within	CREA, Above	EOS, Unknown	EOS, Below	EOS, Within	EOS, Above	HAEM, Unknown	HAEM, Below	HAEM, Within	HAEM, Above	HAEMO, Unknown	HAEMO, Below	HAEMO, Within	HAEMO, Above	LYMPH, Unknown	LYMPH, Below	LYMPH, Within	LYMPH, Above	MONO, Unknown	MONO, Below	MONO, Within	MONO, Above	NEU, Unknown	NEU, Below	NEU, Within	NEU, Above	PLA, Unknown	PLA, Below	PLA, Within	PLA, Above	RBC, Unknown	RBC, Below	RBC, Within	RBC, Above	UR, Unknown	UR, Below	UR, Within	UR, Above	WBC, Unknown	WBC, Below	WBC, Within	WBC, Above
GSK732461 Group	0	0	15	0	0	0	15	0	0	2	12	1	0	0	15	0	0	0	15	0	0	0	15	0	0	0	15	0	0	1	14	0	0	0	14	1	0	0	15	0	0	0	14	1	0	0	15	0	0	0	15	0	0	0	15	0
GSK732461+Nivaquine Group	0	0	13	0	0	0	12	1	1	2	9	1	0	0	13	0	1	0	11	1	1	0	12	0	1	0	12	0	1	1	11	0	1	0	12	0	1	3	9	0	1	0	12	0	1	0	12	0	0	1	12	0	1	1	11	0

Levels of Haematological and Biochemical Parameters

Intervention	Participants (Count of Participants)
	ALT, Unknown	ALT, Below	ALT, Within	ALT, Above	ASA, Unknown	ASA, Below	ASA, Within	ASA, Above	BASO, Unknown	BASO, Below	BASO, Within	BASO, Above	CREA, Unknown	CREA, Below	CREA, Within	CREA, Above	EOS, Unknown	EOS, Below	EOS, Within	EOS, Above	HAEM, Unknown	HAEM, Below	HAEM, Within	HAEM, Above	HAEMO, Unknown	HAEMO, Below	HAEMO, Within	HAEMO, Above	LYMPH, Unknown	LYMPH, Below	LYMPH, Within	LYMPH, Above	MONO, Unknown	MONO, Below	MONO, Within	MONO, Above	NEU, Unknown	NEU, Below	NEU, Within	NEU, Above	PLA, Unknown	PLA, Below	PLA, Within	PLA, Above	RBC, Unknown	RBC, Below	RBC, Within	RBC, Above	UR, Unknown	UR, Below	UR, Within	UR, Above	WBC, Unknown	WBC, Below	WBC, Within	WBC, Above
GSK732461 Group	0	0	15	0	0	0	15	0	0	1	14	0	0	1	12	2	1	1	0	0	0	0	15	0	0	0	15	0	0	0	15	0	0	0	15	0	0	1	14	0	0	0	14	1	0	0	15	0	0	0	15	0	0	0	15	0
GSK732461+Nivaquine Group	0	0	13	0	0	0	13	0	0	3	10	0	0	1	11	1	1	1	0	1	0	0	13	0	0	0	13	0	0	0	13	0	0	0	11	2	0	2	10	1	0	0	13	0	0	0	13	0	0	0	12	1	0	0	12	1

Magnitude of Antigen Specific CD4+ T Cells Expressing at Least 2 Cytokines

Magnitude was defined as the frequency of CD4+ T cells group-specific antigen (Gag) proteins 17, 24, negative regulatory factor (Nef), reverse transcriptase (RT) and fusion protein of all 4 antigens (F4co). Determination of F4co was done by stimulating the F4 antigen with a peptide pool spanning (pool_F4co) or by adding individual frequencies of the CD8+ T cell response to each of the 4 antigens (F4co_est). Among the cytokines expressed were IL-2, TNF-α and INF-γ. (NCT00972725)
Timeframe: At Day 0, 7, 14, 30 and 180

Intervention	T cells/million cells (Median)
	RT, Day 0	RT, Day 7	RT, Day 14	RT, Day 30	RT, Day 180	Nef, Day 0	Nef, Day 7	Nef, Day 14	Nef, Day 30	Nef, Day 180	P17, Day 0	P17, Day 7	P17, Day 14	P17, Day 30	P17, Day 180	P24, Day 0	P24, Day 7	P24, Day 14	P24, Day 30	P24, Day 180	Pool_F4co, Day 0	Pool_F4co, Day 7	Pool_F4co, Day 14	Pool_F4co, Day 30	Pool_F4co, Day 180	F4co_est, Day 0	F4co_est, Day 7	F4co_est, Day 14	F4co_est, Day 30	F4co_est, Day 180
GSK732461 Group	1125.50	3286.00	3461.00	2459.00	1684.00	161.00	739.00	560.00	386.00	306.50	176.00	500.00	503.00	346.00	523.00	434.00	911.00	827.00	793.00	536.50	2006.50	5515.00	5651.00	4138.00	2856.50	1974.50	6613.00	6035.00	4589.00	3079.00
GSK732461+Nivaquine Group	846.00	2407.00	3162.00	2088.00	1205.00	259.00	586.50	890.00	627.00	305.00	154.00	464.00	453.00	397.00	278.00	477.00	872.50	1198.00	641.00	530.00	1421.00	3881.00	4898.00	3791.00	2238.00	2000.00	4390.00	5272.00	4407.00	2530.00

Magnitude of Antigen Specific CD8+ T Cells Expressing at Least One Cytokine

Magnitude was defined as the frequency of CD8+ T cells group-specific antigen (Gag) proteins 17, 24; negative regulatory factor (Nef); reverse transcriptase (RT) and fusion protein of all 4 antigens (F4co). Determination of F4co was done by stimulating the F4 antigen with a peptide pool spanning (pool_F4co) or by adding individual frequencies of the CD8+ T cell response to each of the 4 antigens (F4co_est). Among the cytokines expressed were IL-2, TNF-α and INF-γ. (NCT00972725)
Timeframe: At Day 0, 7, 14, 30 and 180

Intervention	T cells/million cells (Median)
	RT, D0	RT, D7	RT, D14	RT, D30	RT, D180	Nef, D0	Nef, D7	Nef, D14	Nef, D30	Nef, D180	P17, D0	P17, D7	P17, D14	P17, D30	P17, D180	P24, D0	P24, D7	P24, D14	P24, D30	P24, D180	Pool_F4co, D0	Pool_F4co, D7	Pool_F4co, D14	Pool_F4co, D30	Pool_F4co, D180	F4co_est, D0	F4co_est, D7	F4co_est, D14	F4co_est, D30	F4co_est, D180
GSK732461 Group	89.00	137.00	102.00	85.00	48.50	71.00	84.00	99.00	116.00	66.00	76.00	88.00	84.00	98.00	80.00	77.50	54.00	91.00	81.00	45.00	148.00	129.00	118.00	122.00	74.00	398.00	451.00	450.00	380.00	287.50
GSK732461+Nivaquine Group	79.00	127.50	94.00	57.00	14.00	75.00	63.50	123.00	61.00	39.00	104.00	109.50	124.00	18.00	55.00	68.00	93.50	83.00	120.00	62.00	76.00	218.50	92.00	68.00	65.00	373.00	448.50	478.00	290.00	226.00

Number of Subjects With Frequency of Cluster of Differentiation (CD4+) T Cells Expressing at Least 2 Cytokines to at Least 1, 2, 3 or All 4 Antigens

Among expressed cytokines were interleukin-2 (IL-2), tumour necrosis factor alpha (TNF-α) and interferon gamma (INF-γ), as determined by ICS. (NCT00972725)
Timeframe: At Day 0, 7, 14, 30 and 180

Intervention	Participants (Count of Participants)
	1 antigen, Day 0	1 antigen, Day 7	1 antigen, Day 14	1 antigen, Day 30	1 antigen, Day 180	2 antigens, Day 0	2 antigens, Day 7	2 antigens, Day 14	2 antigens, Day 30	2 antigens, Day 180	3 antigens, Day 0	3 antigens, Day 7	3 antigens, Day 14	3 antigens, Day 30	3 antigens, Day 180	4 antigens, Day 0	4 antigens, Day 7	4 antigens, Day 14	4 antigens, Day 30	4 antigens, Day 180
GSK732461 Group	11	12	12	13	14	11	11	11	13	13	4	10	10	10	9	3	8	8	6	4
GSK732461+Nivaquine Group	12	12	12	8	13	10	11	12	7	11	6	10	10	7	10	1	6	6	7	3

Number of Subjects With Frequency of Cluster of Differentiation 8 (CD8+) T Cells Expressing at Least One Cytokine to at Least 1, 2, 3 or All 4 Antigens

Among expressed cytokines were interleukin-2 (IL-2), tumour necrosis factor alpha (TNF-α) and interferon gamma (INF-γ), as determined by intracellular cytokine staining (ICS). (NCT00972725)
Timeframe: At Day 14

Intervention	Participants (Count of Participants)
	At least 1 antigen, Day 14	At least 2 antigens, Day 14	At least 3 antigens, Day 14	At least 4 antigens, Day 14
GSK732461 Group	3	0	0	0
GSK732461+Nivaquine Group	1	0	0	0

Number of Subjects With Solicited General Symptoms

Assessed solicited general symptoms were fatigue, temperature [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)], gastrointestinal symptoms [nausea, vomiting, diarrhoea and/or abdominal pain] and headache. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever > 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. (NCT00972725)
Timeframe: During the 7 Day (Days 0-6) post-vaccination period

Intervention	Participants (Count of Participants)
	Any Fatigue	Grade 3 Fatigue	Related Fatigue	Any Gastrointestinal	Grade 3 Gastrointestinal	Related Gastrointestinal	Any Headache	Grade 3 Headache	Related Headache	Any Temperature	Grade 3 Temperature	Related Temperature
GSK732461 Group	14	3	11	5	0	3	13	0	10	10	1	9
GSK732461+Nivaquine Group	9	3	9	6	1	4	9	3	8	8	0	7

Number of Subjects With Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site. (NCT00972725)
Timeframe: During the 7 Day (Days 0-6) post-vaccination period

Intervention	Participants (Count of Participants)
	Any Pain	Grade 3 Pain	Any Redness	Grade 3 Redness	Any Swelling	Grade 3 Swelling
GSK732461 Group	14	2	6	1	5	2
GSK732461+Nivaquine Group	13	1	3	0	3	0

Number of Subjects With Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset out-side the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination. (NCT00972725)
Timeframe: During the 32 Day (Days 2-29) post-chloroquine administration and during the 30 Day (Days 0-29) post-vaccine administration period

Intervention	Participants (Count of Participants)
	Any AEs	Grade 3 AEs	Related AEs
GSK732461 Group	13	2	8
GSK732461+Nivaquine Group	8	3	5

Antibody Titers Against p17, p24, Nef, RT and F4co Antigens

Anti-p17, -p24, -Nef, -RT and -F4co antibody titers were measured by Enzyme Linked Immunosorbent Assay (ELISA) and presented as geometric mean titers (GMTs). (NCT00434512)
Timeframe: At Month 0, Day 44, Month 2, Month 6 and Month 12

,,,,,

Intervention	Titers (Geometric Mean)
	Anti-p17, Day 0	Anti-p17, Day 44	Anti-p17, Month 2	Anti-p17, Month 6	Anti-p17, Month 12	Anti-p24, Day 0	Anti-p24, Day 44	Anti-p24, Month 2	Anti-p24, Month 6	Anti-p24, Month 12	Anti-Nef, Day 0	Anti-Nef, Day 44	Anti-Nef, Month 2	Anti-Nef, Month 6	Anti-Nef, Month 12	Anti-RT, Day 0	Anti-RT, Day 44	Anti-RT, Month 2	Anti-RT, Month 6	Anti-RT, Month 12	Anti-F4co, Month 0	Anti-F4co, Day 44	Anti-F4co, Month 2	Anti-F4co, Month 6	Anti-F4co, Month 12
SB732461 adjuvanted_HD Group	96.3	1499.7	1189.3	146.6	133.7	62.1	21089.3	12541.9	2082.9	762.6	136.1	26844.9	17926.2	2712.2	1330.2	62.5	11812.0	6959.8	883.9	471.1	21.5	12359.6	5438.7	1081.4	837.5
SB732461 adjuvanted_LD Group	93.5	824.9	553.2	169.0	128.0	59.5	18765.3	12453.4	2800.2	1254.8	120.0	27263.0	12467.6	2133.7	1032.4	62.5	8979.1	5761.6	705.5	462.1	21.0	7027.2	4770.3	1303.1	790.7
SB732461 adjuvanted_MD Group	93.5	1416.4	808.2	167.4	140.5	59.5	18788.8	11238.4	1898.0	840.6	129.6	20504.6	12378.1	1617.1	710.4	64.2	10019.9	6543.3	902.5	428.7	21.0	11151.6	4607.8	1081.4	1154.0
SB732461 Non-adjuvanted_HD Group	93.5	104.2	93.5	93.5	93.5	59.5	88.8	87.4	83.0	70.8	116.0	184.6	168.4	173.8	116.0	69.1	100.1	96.5	62.5	72.0	21.0	42.7	31.5	31.0	33.1
SB732461 Non-adjuvanted_LD Group	93.5	93.5	93.5	93.5	93.5	59.5	65.3	69.7	59.5	59.5	116.0	157.8	152.1	144.9	135.9	62.5	62.5	76.7	71.4	74.3	21.0	23.8	26.1	22.9	25.1
SB732461 Non-adjuvanted_MD Group	109.5	133.3	107.6	93.5	93.5	64.7	120.3	97.5	59.5	59.5	138.0	229.2	185.3	135.4	154.2	62.5	95.5	85.6	75.7	62.5	24.6	42.1	34.7	25.5	23.6

Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers

Antigen-specific CD4+ T-cells can express CD40 ligand (CD40-L) and produce the cytokines Interleukin 2 (IL-2) and/or Tumor Necrosis Factor alpha (TNF-α) and/or Interferon-gamma (IFN-γ). Frequency of CD4+ T-cells expressing markers in response to the F4co fusion protein (all antigens) was estimated by adding individual frequencies of CD4+ T-cells to each of the 4 antigens (p17, p24, Nef, RT). Results are presented as determined by Intracellular Cytokine Staining (ICS). (NCT00434512)
Timeframe: At Month 0, Day 44, Month 2, Month 6 and Month 12

,,,,,

Intervention	CD4+ T-cells/million T-cells (Mean)
	p17, Day 0	p17, Day 44	p17, Month 2	p17, Month 6	p17, Month 12	p24, Day 0	p24, Day 44	p24, Month 2	p24, Month 6	p24, Month 12	Nef, Day 0	Nef, Day 44	Nef, Month 2	Nef, Month 6	Nef, Month 12	RT, Day 0	RT, Day 44	RT, Month 2	RT, Month 6	RT, Month 12
SB732461 adjuvanted_HD Group	39.80	850.86	682.70	398.62	501.60	68.31	1661.03	1253.06	562.26	718.17	80.51	1034.77	826.45	435.71	485.23	148.37	3041.74	2471.94	1198.74	1347.26
SB732461 adjuvanted_LD Group	23.58	1937.11	1308.50	791.54	784.57	60.05	3536.04	2429.89	1320.63	1282.00	52.74	2133.76	1470.00	906.78	786.23	107.84	7843.87	5291.91	3157.02	2965.34
SB732461 adjuvanted_MD Group	32.75	777.68	562.63	411.95	374.65	77.98	1662.85	1306.25	775.63	766.55	60.70	1039.80	751.35	574.18	432.85	81.00	3231.88	2575.98	1539.85	1433.63
SB732461 Non-adjuvanted_HD Group	30.44	69.67	23.00	94.13	31.00	93.56	161.56	121.89	143.63	101.78	157.56	138.44	99.78	73.75	50.44	47.22	297.78	283.56	103.88	132.33
SB732461 Non-adjuvanted_LD Group	21.89	59.75	15.11	57.78	32.13	46.67	80.13	49.11	53.78	34.25	18.67	61.00	51.78	66.67	60.50	158.56	328.25	365.00	46.67	54.50
SB732461 Non-adjuvanted_MD Group	5.56	104.22	65.56	101.38	101.25	46.56	243.00	145.56	83.75	74.00	30.00	87.11	69.89	29.75	45.63	60.78	311.00	261.78	140.75	99.38

Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker

,,,,,

Intervention	CD4+ T-cells/million T-cells (Mean)
	p17, Day 0	p17, Day 44	p17, Month 2	p17, Month 6	p17, Month 12	p24, Day 0	p24, Day 44	p24, Month 2	p24, Month 6	p24, Month 12	Nef, Day 0	Nef, Day 44	Nef, Month 2	Nef, Month 6	Nef, Month 12	RT, Day 0	RT, Day 44	RT, Month 2	RT, Month 6	RT, Month 12
SB732461 adjuvanted_HD Group	30.60	740.91	625.88	360.32	462.29	52.14	1446.17	1120.58	562.26	718.17	58.97	862.20	713.33	374.32	426.34	63.80	2518.71	2107.61	1198.74	1347.26
SB732461 adjuvanted_LD Group	17.95	1724.07	1238.82	762.59	766.55	30.60	3078.59	2228.00	1320.63	1282.00	40.02	1822.50	1307.89	855.13	722.80	52.53	6760.11	4731.64	3157.02	2965.34
SB732461 adjuvanted_MD Group	21.90	696.78	517.38	376.80	345.55	54.95	1441.93	1171.50	775.63	766.55	39.53	872.83	678.78	532.80	404.98	52.85	2787.43	2304.75	1539.85	1433.63
SB732461 Non-adjuvanted_HD Group	7.89	57.22	30.22	61.63	25.00	29.11	119.22	87.22	143.63	101.78	78.11	108.22	73.00	38.75	42.56	21.33	262.00	209.89	103.88	132.33
SB732461 Non-adjuvanted_LD Group	32.56	58.25	17.33	22.22	28.50	51.67	47.25	31.56	53.78	34.25	25.78	52.63	30.56	46.67	23.00	77.44	107.75	109.22	46.67	54.50
SB732461 Non-adjuvanted_MD Group	16.78	102.00	60.11	80.50	70.13	27.56	205.22	142.67	83.75	74.00	22.00	89.00	75.67	36.25	20.75	31.67	250.00	242.22	140.75	99.38

Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens

Antigen-specific CD4+ T-cells can express cluster of differentiation 40-ligand (CD40-L) and produce the cytokines Interleukin 2 (IL-2) and/or Tumor Necrosis Factor alpha (TNF-α) and/or Interferon-gamma (IFN-γ). The frequency of antigen specific CD4+T-cells was calculated as the difference between the frequency of CD4+T-cells producing at least 2 cytokines (among IFN-g, IL-2, TNF-a and/or CD40L), upon in vitro stimulation with the peptide pools derived from the antigen minus the frequency of CD4+T-cells producing at least 2 cytokines upon in vitro stimulation in medium only.A responder was a subject with an antigen-stimulated CD4+T cells response greater than or equal to the cut-off value. The same cut-off value was used for all subjects and all antigen responses post-vaccination. It was calculated from the pre-vaccination CD4+T cell responses (the frequency of antigen-stimulated CD4+T cells expressing at least two markers; i.e. all doubles) for all subjects. (NCT00434512)
Timeframe: At Day 44

,,,,,

Intervention	Participants (Count of Participants)
	At least 1 antigen	At least 2 antigens	At least 3 antigens	All 4 antigens
SB732461 adjuvanted_HD Group	35	34	31	23
SB732461 adjuvanted_LD Group	46	46	46	37
SB732461 adjuvanted_MD Group	40	38	34	22
SB732461 Non-adjuvanted_HD Group	2	2	0	0
SB732461 Non-adjuvanted_LD Group	1	0	0	0
SB732461 Non-adjuvanted_MD Group	2	1	1	0

Number of Subjects With Any and Grade 3 Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site. (NCT00434512)
Timeframe: During the 7-day (Days 0-6) follow-up period after each vaccination and overall (across doses)

,,,,,

Intervention	Participants (Count of Participants)
	Any Pain, Dose 1	Grade 3 Pain, Dose 1	Any Redness, Dose 1	Grade 3 Redness, Dose 1	Any Swelling, Dose 1	Grade 3 Swelling, Dose 1	Any Pain, Dose 2	Grade 3 Pain, Dose 2	Any Redness, Dose 2	Grade 3 Redness, Dose 2	Any Swelling, Dose 2	Grade 3 Swelling, Dose 2	Any Pain, Overall	Grade 3 Pain, Overall	Any Redness, Overall	Grade 3 Redness, Overall	Any Swelling, Overall	Grade 3 Swelling, Overall
SB732461 adjuvanted_HD Group	49	4	9	2	5	1	48	6	25	10	17	3	50	10	25	12	19	4
SB732461 adjuvanted_LD Group	49	4	5	3	9	5	47	6	14	5	11	4	49	7	14	7	13	6
SB732461 adjuvanted_MD Group	49	1	18	9	12	2	49	4	17	11	13	2	50	5	23	13	18	3
SB732461 Non-adjuvanted_HD Group	2	0	0	0	0	0	4	0	0	0	0	0	5	0	0	0	0	0
SB732461 Non-adjuvanted_LD Group	2	0	0	0	0	0	3	0	0	0	0	0	3	0	0	0	0	0
SB732461 Non-adjuvanted_MD Group	0	0	0	0	0	0	2	0	0	0	0	0	2	0	0	0	0	0

Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

Assessed solicited general symptoms were fatigue, fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)], headache, myalgia, sweating, gastrointestinal symptoms(nausea, vomiting, diarrhea, and/or abdominal pain). Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever > 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. (NCT00434512)
Timeframe: During the 7-day (Days 0-6) follow-up period after each vaccination and overall (across doses)

,,,,,

Intervention	Participants (Count of Participants)
	Any Fatigue, Dose 1	Grade 3 Fatigue, Dose 1	Related Fatigue, Dose 1	Any Fever, Dose 1	Grade 3 Fever, Dose 1	Related Fever, Dose 1	Any Gastrointestinal, Dose 1	Grade 3 Gastrointestinal, Dose 1	Related Gastrointestinal, Dose 1	Any Headache, Dose 1	Grade 3 Headache, Dose 1	Related Headache, Dose 1	Any Myalgia, Dose 1	Grade 3 Myalgia, Dose 1	Related Myalgia, Dose 1	Any Sweating, Dose 1	Grade 3 Sweating, Dose 1	Related Sweating, Dose 1	Any Fatigue, Dose 2	Grade 3 Fatigue, Dose 2	Related Fatigue, Dose 2	Any Fever, Dose 2	Grade 3 Fever, Dose 2	Related Fever, Dose 2	Any Gastrointestinal, Dose 2	Grade 3 Gastrointestinal, Dose 2	Related Gastrointestinal, Dose 2	Any Headache, Dose 2	Grade 3 Headache, Dose 2	Related Headache, Dose 2	Any Myalgia, Dose 2	Grade 3 Myalgia, Dose 2	Related Myalgia, Dose 2	Any Sweating, Dose 2	Grade 3 Sweating, Dose 2	Related Sweating, Dose 2	Any Fatigue, Overall	Grade 3 Fatigue, Overall	Related Fatigue, Overall	Any Fever, Overall	Grade 3 Fever, Overall	Related Fever, Overall	Any Gastrointestinal, Overall	Grade 3 Gastrointestinal, Overall	Related Gastrointestinal, Overall	Any Headache, Overall	Grade 3 Headache, Overall	Related Headache, Overall	Any Myalgia, Overall	Grade 3 Myalgia, Overall	Related Myalgia, Overall	Any Sweating, Overall	Grade 3 Sweating, Overall	Related Sweating, Overall
SB732461 adjuvanted_HD Group	33	1	32	3	0	3	8	0	5	24	2	21	23	4	21	11	0	10	44	11	44	25	1	25	13	2	11	37	6	37	28	7	28	23	4	23	46	12	46	26	1	26	17	2	13	41	8	41	36	8	35	26	4	26
SB732461 adjuvanted_LD Group	27	2	26	3	0	3	9	0	8	24	2	20	13	0	13	7	0	6	39	9	39	29	3	29	20	2	19	38	8	37	31	5	31	28	3	26	40	11	40	30	3	30	23	2	22	42	10	40	31	5	31	28	3	27
SB732461 adjuvanted_MD Group	28	0	24	3	0	3	9	0	6	21	0	19	20	0	19	8	0	6	43	7	43	29	2	29	15	2	12	37	5	37	31	6	31	24	2	24	47	7	46	29	2	29	21	2	16	42	5	42	35	6	35	27	2	27
SB732461 Non-adjuvanted_HD Group	5	0	3	0	0	0	1	0	1	3	0	2	1	0	1	2	0	2	4	0	3	0	0	0	2	0	2	2	0	2	1	0	1	1	0	1	6	0	5	0	0	0	2	0	2	5	0	4	2	0	2	3	0	3
SB732461 Non-adjuvanted_LD Group	3	0	2	0	0	0	1	0	1	2	0	0	2	0	2	0	0	0	3	0	3	0	0	0	1	0	1	2	0	1	0	0	0	1	0	1	5	0	5	0	0	0	2	0	2	4	0	1	2	0	2	1	0	1
SB732461 Non-adjuvanted_MD Group	5	0	4	0	0	0	1	0	0	4	0	3	1	0	1	0	0	0	2	0	1	0	0	0	1	0	1	1	0	1	1	0	1	1	0	1	5	0	4	0	0	0	2	0	1	4	0	3	1	0	1	1	0	1

Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination. (NCT00434512)
Timeframe: During the 30-day (Days 0-29) follow-up period after vaccination (across doses)

,,,,,

Intervention	Participants (Count of Participants)
	Any AE(s)	Grade 3 AE(s)	Related AE(s)
SB732461 adjuvanted_HD Group	33	6	15
SB732461 adjuvanted_LD Group	42	9	22
SB732461 adjuvanted_MD Group	30	5	15
SB732461 Non-adjuvanted_HD Group	7	0	1
SB732461 Non-adjuvanted_LD Group	5	0	0
SB732461 Non-adjuvanted_MD Group	6	1	0

Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44

The frequency distribution of values below, within and above normal ranges, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells [RBC] count, haemoglobin, haematocrit, white blood cell [WBC] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase [ALT] and aspartate aminotransferase [AST]. (NCT00434512)
Timeframe: At Day 44

Intervention	Participants (Count of Participants)
	RBC72427296				RBC72427297	RBC72427290	RBC72427299	RBC72427298	RBC72427295	Haemoglobin72427297	Haemoglobin72427295	Haemoglobin72427290	Haemoglobin72427296	Haemoglobin72427298	Haemoglobin72427299	Hematocrit72427290	Hematocrit72427296	Hematocrit72427297	Hematocrit72427298	Hematocrit72427299	Hematocrit72427295	WBC72427297	WBC72427296	WBC72427290	WBC72427298	WBC72427299	WBC72427295	Neutrophils72427290	Neutrophils72427296	Neutrophils72427298	Neutrophils72427297	Neutrophils72427299	Neutrophils72427295	Lymphocytes72427290	Lymphocytes72427296	Lymphocytes72427298	Lymphocytes72427297	Lymphocytes72427295	Lymphocytes72427299	Monocytes72427290	Monocytes72427297	Monocytes72427298	Monocytes72427295	Monocytes72427296	Monocytes72427299	Eosinophils72427290	Eosinophils72427296	Eosinophils72427297	Eosinophils72427295	Eosinophils72427298	Eosinophils72427299	Basophils72427290	Basophils72427295	Basophils72427299	Basophils72427296	Basophils72427297	Basophils72427298	Platelets72427290	Platelets72427295	Platelets72427298	Platelets72427296	Platelets72427297	Platelets72427299	Sodium72427297	Sodium72427295	Sodium72427296	Sodium72427290	Sodium72427298	Sodium72427299	Potassium72427290	Potassium72427295	Potassium72427296	Potassium72427297	Potassium72427298	Potassium72427299	Urea Nitrogen72427290	Urea Nitrogen72427296	Urea Nitrogen72427295	Urea Nitrogen72427297	Urea Nitrogen72427298	Urea Nitrogen72427299	Creatinine72427298	Creatinine72427296	Creatinine72427290	Creatinine72427297	Creatinine72427299	Creatinine72427295	AST72427290	AST72427298	AST72427299	AST72427296	AST72427297	AST72427295	ALT72427297	ALT72427298	ALT72427299	ALT72427295	ALT72427290	ALT72427296
	Unknown	Below	Within	Above
SB732461 adjuvanted_LD Group	49
SB732461 adjuvanted_HD Group	46
SB732461 adjuvanted_MD Group	2
SB732461 Non-adjuvanted_HD Group	2
SB732461 adjuvanted_HD Group	4
SB732461 adjuvanted_MD Group	48
SB732461 adjuvanted_HD Group	44
SB732461 Non-adjuvanted_MD Group	0
SB732461 adjuvanted_LD Group	0
SB732461 Non-adjuvanted_MD Group	1
SB732461 adjuvanted_MD Group	4
SB732461 adjuvanted_LD Group	48
SB732461 Non-adjuvanted_MD Group	9
SB732461 adjuvanted_MD Group	46
SB732461 adjuvanted_LD Group	2
SB732461 adjuvanted_MD Group	3
SB732461 adjuvanted_LD Group	47
SB732461 adjuvanted_MD Group	47
SB732461 Non-adjuvanted_HD Group	8
SB732461 adjuvanted_LD Group	1
SB732461 Non-adjuvanted_HD Group	1
SB732461 adjuvanted_HD Group	45
SB732461 Non-adjuvanted_LD Group	6
SB732461 adjuvanted_LD Group	44
SB732461 Non-adjuvanted_MD Group	7
SB732461 adjuvanted_MD Group	42
SB732461 Non-adjuvanted_HD Group	6
SB732461 adjuvanted_HD Group	34
SB732461 Non-adjuvanted_LD Group	3
SB732461 adjuvanted_LD Group	6
SB732461 Non-adjuvanted_MD Group	3
SB732461 adjuvanted_MD Group	8
SB732461 Non-adjuvanted_HD Group	4
SB732461 adjuvanted_HD Group	12
SB732461 Non-adjuvanted_LD Group	8
SB732461 adjuvanted_LD Group	46
SB732461 Non-adjuvanted_LD Group	2
SB732461 adjuvanted_LD Group	4
SB732461 adjuvanted_LD Group	50
SB732461 adjuvanted_MD Group	50
SB732461 Non-adjuvanted_MD Group	10
SB732461 Non-adjuvanted_LD Group	1
SB732461 Non-adjuvanted_LD Group	9
SB732461 Non-adjuvanted_HD Group	9
SB732461 adjuvanted_HD Group	43
SB732461 adjuvanted_LD Group	3
SB732461 adjuvanted_HD Group	3
SB732461 adjuvanted_MD Group	0
SB732461 Non-adjuvanted_HD Group	0
SB732461 adjuvanted_MD Group	49
SB732461 Non-adjuvanted_HD Group	10
SB732461 adjuvanted_HD Group	48
SB732461 adjuvanted_MD Group	1
SB732461 adjuvanted_HD Group	2
SB732461 adjuvanted_HD Group	1
SB732461 Non-adjuvanted_LD Group	10
SB732461 adjuvanted_HD Group	47
SB732461 Non-adjuvanted_LD Group	0
SB732461 adjuvanted_HD Group	0

Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0

Intervention	Participants (Count of Participants)
	RBC72427299				RBC72427295	RBC72427290	RBC72427297	RBC72427298	RBC72427296	Haemoglobin72427296	Haemoglobin72427297	Haemoglobin72427298	Haemoglobin72427290	Haemoglobin72427299	Haemoglobin72427295	Hematocrit72427290	Hematocrit72427297	Hematocrit72427298	Hematocrit72427299	Hematocrit72427296	Hematocrit72427295	WBC72427296	WBC72427290	WBC72427297	WBC72427298	WBC72427299	WBC72427295	Neutrophils72427290	Neutrophils72427297	Neutrophils72427298	Neutrophils72427299	Neutrophils72427296	Neutrophils72427295	Lymphocytes72427298	Lymphocytes72427299	Lymphocytes72427295	Lymphocytes72427296	Lymphocytes72427290	Lymphocytes72427297	Monocytes72427296	Monocytes72427297	Monocytes72427299	Monocytes72427295	Monocytes72427298	Monocytes72427290	Eosinophils72427290	Eosinophils72427297	Eosinophils72427295	Eosinophils72427296	Eosinophils72427299	Eosinophils72427298	Basophils72427299	Basophils72427295	Basophils72427290	Basophils72427297	Basophils72427298	Basophils72427296	Platelets72427298	Platelets72427299	Platelets72427295	Platelets72427296	Platelets72427297	Platelets72427290	Sodium72427297	Sodium72427295	Sodium72427290	Sodium72427296	Sodium72427298	Sodium72427299	Potassium72427290	Potassium72427296	Potassium72427297	Potassium72427298	Potassium72427299	Potassium72427295	Urea Nitrogen72427296	Urea Nitrogen72427297	Urea Nitrogen72427299	Urea Nitrogen72427295	Urea Nitrogen72427298	Urea Nitrogen72427290	Creatinine72427298	Creatinine72427299	Creatinine72427295	Creatinine72427297	Creatinine72427290	Creatinine72427296	AST72427290	AST72427298	AST72427296	AST72427297	AST72427299	AST72427295	ALT72427296	ALT72427297	ALT72427290	ALT72427295	ALT72427298	ALT72427299
	Within	Unknown	Below	Above
SB732461 adjuvanted_LD Group	4
SB732461 adjuvanted_LD Group	46
SB732461 Non-adjuvanted_HD Group	1
SB732461 adjuvanted_HD Group	2
SB732461 Non-adjuvanted_HD Group	9
SB732461 adjuvanted_HD Group	48
SB732461 adjuvanted_MD Group	4
SB732461 adjuvanted_HD Group	6
SB732461 adjuvanted_MD Group	45
SB732461 adjuvanted_HD Group	44
SB732461 adjuvanted_HD Group	3
SB732461 adjuvanted_LD Group	43
SB732461 adjuvanted_HD Group	47
SB732461 adjuvanted_LD Group	5
SB732461 Non-adjuvanted_LD Group	1
SB732461 adjuvanted_LD Group	6
SB732461 Non-adjuvanted_LD Group	9
SB732461 adjuvanted_LD Group	44
SB732461 adjuvanted_MD Group	46
SB732461 adjuvanted_LD Group	40
SB732461 Non-adjuvanted_MD Group	7
SB732461 adjuvanted_MD Group	40
SB732461 Non-adjuvanted_HD Group	7
SB732461 adjuvanted_HD Group	39
SB732461 adjuvanted_LD Group	7
SB732461 Non-adjuvanted_MD Group	3
SB732461 adjuvanted_MD Group	10
SB732461 Non-adjuvanted_HD Group	3
SB732461 adjuvanted_HD Group	11
SB732461 Non-adjuvanted_LD Group	7
SB732461 adjuvanted_LD Group	47
SB732461 adjuvanted_MD Group	49
SB732461 Non-adjuvanted_LD Group	3
SB732461 adjuvanted_LD Group	3
SB732461 adjuvanted_HD Group	0
SB732461 Non-adjuvanted_HD Group	10
SB732461 adjuvanted_HD Group	50
SB732461 adjuvanted_MD Group	1
SB732461 Non-adjuvanted_LD Group	10
SB732461 adjuvanted_LD Group	49
SB732461 Non-adjuvanted_MD Group	9
SB732461 Non-adjuvanted_LD Group	0
SB732461 adjuvanted_LD Group	1
SB732461 Non-adjuvanted_MD Group	1
SB732461 adjuvanted_LD Group	50
SB732461 adjuvanted_MD Group	48
SB732461 adjuvanted_MD Group	2
SB732461 Non-adjuvanted_HD Group	0
SB732461 adjuvanted_LD Group	2
SB732461 Non-adjuvanted_MD Group	0
SB732461 adjuvanted_LD Group	48
SB732461 Non-adjuvanted_MD Group	10
SB732461 adjuvanted_MD Group	50
SB732461 adjuvanted_HD Group	49
SB732461 adjuvanted_LD Group	0
SB732461 adjuvanted_MD Group	0
SB732461 adjuvanted_HD Group	1

Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1

Intervention	Participants (Count of Participants)
	RBC72427290				RBC72427296	RBC72427297	RBC72427298	RBC72427295	RBC72427299	Haemoglobin72427298	Haemoglobin72427297	Haemoglobin72427290	Haemoglobin72427296	Haemoglobin72427299	Haemoglobin72427295	Hematocrit72427297	Hematocrit72427295	Hematocrit72427290	Hematocrit72427296	Hematocrit72427298	Hematocrit72427299	WBC72427297	WBC72427296	WBC72427295	WBC72427290	WBC72427298	WBC72427299	Neutrophils72427290	Neutrophils72427295	Neutrophils72427296	Neutrophils72427297	Neutrophils72427298	Neutrophils72427299	Lymphocytes72427290	Lymphocytes72427296	Lymphocytes72427297	Lymphocytes72427298	Lymphocytes72427299	Lymphocytes72427295	Monocytes72427296	Monocytes72427290	Monocytes72427297	Monocytes72427298	Monocytes72427299	Monocytes72427295	Eosinophils72427290	Eosinophils72427299	Eosinophils72427297	Eosinophils72427296	Eosinophils72427298	Eosinophils72427295	Basophils72427299	Basophils72427296	Basophils72427295	Basophils72427290	Basophils72427297	Basophils72427298	Platelets72427290	Platelets72427296	Platelets72427295	Platelets72427298	Platelets72427299	Platelets72427297	Sodium72427290	Sodium72427295	Sodium72427297	Sodium72427296	Sodium72427298	Sodium72427299	Potassium72427295	Potassium72427297	Potassium72427290	Potassium72427296	Potassium72427298	Potassium72427299	Urea Nitrogen72427296	Urea Nitrogen72427298	Urea Nitrogen72427299	Urea Nitrogen72427290	Urea Nitrogen72427297	Urea Nitrogen72427295	Creatinine72427296	Creatinine72427299	Creatinine72427295	Creatinine72427298	Creatinine72427290	Creatinine72427297	AST72427297	AST72427298	AST72427295	AST72427290	AST72427296	AST72427299	ALT72427298	ALT72427295	ALT72427297	ALT72427299	ALT72427290	ALT72427296
	Within	Above	Unknown	Below
SB732461 Non-adjuvanted_MD Group	10
SB732461 adjuvanted_LD Group	48
SB732461 adjuvanted_LD Group	4
SB732461 adjuvanted_MD Group	49
SB732461 adjuvanted_HD Group	50
SB732461 adjuvanted_MD Group	0
SB732461 adjuvanted_HD Group	0
SB732461 adjuvanted_MD Group	7
SB732461 adjuvanted_HD Group	4
SB732461 Non-adjuvanted_LD Group	10
SB732461 adjuvanted_MD Group	42
SB732461 Non-adjuvanted_HD Group	10
SB732461 adjuvanted_HD Group	45
SB732461 Non-adjuvanted_LD Group	0
SB732461 adjuvanted_MD Group	1
SB732461 Non-adjuvanted_HD Group	0
SB732461 adjuvanted_HD Group	1
SB732461 Non-adjuvanted_MD Group	1
SB732461 adjuvanted_MD Group	5
SB732461 adjuvanted_LD Group	46
SB732461 Non-adjuvanted_MD Group	9
SB732461 adjuvanted_MD Group	44
SB732461 adjuvanted_HD Group	43
SB732461 adjuvanted_LD Group	2
SB732461 adjuvanted_HD Group	3
SB732461 adjuvanted_LD Group	47
SB732461 adjuvanted_LD Group	1
SB732461 Non-adjuvanted_LD Group	7
SB732461 adjuvanted_LD Group	38
SB732461 Non-adjuvanted_MD Group	6
SB732461 adjuvanted_MD Group	39
SB732461 adjuvanted_HD Group	31
SB732461 Non-adjuvanted_LD Group	3
SB732461 adjuvanted_LD Group	11
SB732461 Non-adjuvanted_MD Group	4
SB732461 adjuvanted_MD Group	11
SB732461 Non-adjuvanted_HD Group	5
SB732461 adjuvanted_HD Group	19
SB732461 Non-adjuvanted_LD Group	9
SB732461 adjuvanted_LD Group	44
SB732461 adjuvanted_HD Group	47
SB732461 Non-adjuvanted_LD Group	1
SB732461 adjuvanted_LD Group	6
SB732461 adjuvanted_MD Group	6
SB732461 adjuvanted_LD Group	50
SB732461 adjuvanted_LD Group	0
SB732461 adjuvanted_HD Group	2
SB732461 adjuvanted_HD Group	48
SB732461 Non-adjuvanted_MD Group	0
SB732461 adjuvanted_MD Group	48
SB732461 Non-adjuvanted_HD Group	9
SB732461 adjuvanted_MD Group	2
SB732461 Non-adjuvanted_HD Group	1
SB732461 adjuvanted_MD Group	47
SB732461 adjuvanted_MD Group	3
SB732461 adjuvanted_HD Group	5
SB732461 adjuvanted_MD Group	50
SB732461 adjuvanted_HD Group	49
SB732461 adjuvanted_LD Group	49

Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12

Intervention	Participants (Count of Participants)
	Haemoglobin72427296				Haemoglobin72427297	Haemoglobin72427290	Haemoglobin72427298	Haemoglobin72427299	Haemoglobin72427295	Monocytes72427297	Monocytes72427295	Monocytes72427290	Monocytes72427296	Monocytes72427298	Monocytes72427299	Sodium72427297	Sodium72427295	Sodium72427296	Sodium72427298	Sodium72427290	Sodium72427299	Potassium72427296	Potassium72427297	Potassium72427290	Potassium72427298	Potassium72427299	Potassium72427295	RBC72427296	RBC72427295	RBC72427290	RBC72427297	RBC72427298	RBC72427299	Lymphocytes72427290	Lymphocytes72427299	Lymphocytes72427295	Lymphocytes72427296	Lymphocytes72427297	Lymphocytes72427298	Platelets72427296	Platelets72427299	Platelets72427297	Platelets72427298	Platelets72427290	Platelets72427295	Urea Nitrogen72427298	Urea Nitrogen72427299	Urea Nitrogen72427295	Urea Nitrogen72427296	Urea Nitrogen72427290	Urea Nitrogen72427297	Hematocrit72427297	Hematocrit72427290	Hematocrit72427296	Hematocrit72427298	Hematocrit72427299	Hematocrit72427295	Creatinine72427298	Creatinine72427290	Creatinine72427296	Creatinine72427297	Creatinine72427295	Creatinine72427299	AST72427297	AST72427298	AST72427290	AST72427296	AST72427299	AST72427295	ALT72427297	ALT72427298	ALT72427290	ALT72427299	ALT72427296	ALT72427295	Neutrophils72427297	Neutrophils72427290	Neutrophils72427296	Neutrophils72427298	Neutrophils72427299	Neutrophils72427295	Basophils72427299	Basophils72427296	Basophils72427295	Basophils72427290	Basophils72427297	Basophils72427298	Eosinophils72427296	Eosinophils72427299	Eosinophils72427297	Eosinophils72427298	Eosinophils72427290	Eosinophils72427295	WBC72427290	WBC72427296	WBC72427297	WBC72427298	WBC72427299	WBC72427295
	Whitin	Above	Unknown	Below
SB732461 adjuvanted_MD Group	2
SB732461 adjuvanted_LD Group	47
SB732461 Non-adjuvanted_MD Group	8
SB732461 adjuvanted_MD Group	47
SB732461 Non-adjuvanted_MD Group	0
SB732461 Non-adjuvanted_MD Group	6
SB732461 adjuvanted_MD Group	38
SB732461 Non-adjuvanted_HD Group	8
SB732461 adjuvanted_HD Group	41
SB732461 Non-adjuvanted_MD Group	3
SB732461 adjuvanted_MD Group	10
SB732461 Non-adjuvanted_HD Group	2
SB732461 adjuvanted_HD Group	8
SB732461 adjuvanted_MD Group	44
SB732461 adjuvanted_HD Group	49
SB732461 adjuvanted_LD Group	4
SB732461 adjuvanted_MD Group	5
SB732461 Non-adjuvanted_HD Group	1
SB732461 adjuvanted_LD Group	48
SB732461 Non-adjuvanted_HD Group	9
SB732461 adjuvanted_LD Group	49
SB732461 adjuvanted_MD Group	48
SB732461 adjuvanted_HD Group	47
SB732461 adjuvanted_LD Group	43
SB732461 Non-adjuvanted_MD Group	7
SB732461 adjuvanted_MD Group	43
SB732461 adjuvanted_HD Group	45
SB732461 adjuvanted_MD Group	6
SB732461 adjuvanted_LD Group	0
SB732461 adjuvanted_LD Group	46
SB732461 adjuvanted_MD Group	49
SB732461 adjuvanted_HD Group	48
SB732461 adjuvanted_LD Group	3
SB732461 Non-adjuvanted_MD Group	2
SB732461 Non-adjuvanted_MD Group	9
SB732461 Non-adjuvanted_LD Group	1
SB732461 Non-adjuvanted_LD Group	9
SB732461 Non-adjuvanted_LD Group	0
SB732461 adjuvanted_LD Group	5
SB732461 Non-adjuvanted_MD Group	1
SB732461 adjuvanted_MD Group	7
SB732461 adjuvanted_LD Group	41
SB732461 adjuvanted_MD Group	42
SB732461 adjuvanted_HD Group	46
SB732461 Non-adjuvanted_LD Group	10
SB732461 Non-adjuvanted_LD Group	2
SB732461 adjuvanted_HD Group	2
SB732461 adjuvanted_LD Group	1
SB732461 adjuvanted_MD Group	1
SB732461 adjuvanted_HD Group	1
SB732461 adjuvanted_MD Group	3
SB732461 adjuvanted_HD Group	6
SB732461 Non-adjuvanted_LD Group	8
SB732461 adjuvanted_LD Group	45
SB732461 adjuvanted_MD Group	46
SB732461 Non-adjuvanted_HD Group	10
SB732461 adjuvanted_HD Group	43
SB732461 adjuvanted_LD Group	2
SB732461 adjuvanted_MD Group	0
SB732461 Non-adjuvanted_HD Group	0
SB732461 adjuvanted_HD Group	0

Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2

The frequency distribution of values below, within and above normal ranges, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells [RBC] count, haemoglobin, haematocrit, white blood cell [RBC] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase [ALT] and aspartate aminotransferase [AST]. (NCT00434512)
Timeframe: At Month 2

Intervention	Participants (Count of Participants)
	RBC72427297				RBC72427298	RBC72427299	RBC72427296	RBC72427290	RBC72427295	Haemoglobin72427290	Haemoglobin72427296	Haemoglobin72427298	Haemoglobin72427295	Haemoglobin72427297	Haemoglobin72427299	Hematocrit72427290	Hematocrit72427298	Hematocrit72427299	Hematocrit72427295	Hematocrit72427297	Hematocrit72427296	WBC72427297	WBC72427299	WBC72427295	WBC72427290	WBC72427296	WBC72427298	Neutrophils72427297	Neutrophils72427296	Neutrophils72427299	Neutrophils72427295	Neutrophils72427290	Neutrophils72427298	Lymphocytes72427290	Lymphocytes72427296	Lymphocytes72427297	Lymphocytes72427298	Lymphocytes72427295	Lymphocytes72427299	Monocytes72427296	Monocytes72427297	Monocytes72427295	Monocytes72427290	Monocytes72427299	Monocytes72427298	Eosinophils72427297	Eosinophils72427298	Eosinophils72427299	Eosinophils72427290	Eosinophils72427296	Eosinophils72427295	Basophils72427290	Basophils72427296	Basophils72427298	Basophils72427297	Basophils72427299	Basophils72427295	Platelets72427290	Platelets72427296	Platelets72427298	Platelets72427295	Platelets72427297	Platelets72427299	Sodium72427290	Sodium72427296	Sodium72427297	Sodium72427299	Sodium72427295	Sodium72427298	Potassium72427290	Potassium72427296	Potassium72427298	Potassium72427299	Potassium72427295	Potassium72427297	Urea Nitrogen72427290	Urea Nitrogen72427296	Urea Nitrogen72427299	Urea Nitrogen72427295	Urea Nitrogen72427297	Urea Nitrogen72427298	Creatinine72427290	Creatinine72427298	Creatinine72427299	Creatinine72427295	Creatinine72427296	Creatinine72427297	AST72427290	AST72427298	AST72427299	AST72427297	AST72427296	AST72427295	ALT72427297	ALT72427298	ALT72427290	ALT72427296	ALT72427299	ALT72427295
	Above	Unknown	Below	Within
SB732461 adjuvanted_MD Group	2
SB732461 adjuvanted_MD Group	47
SB732461 adjuvanted_LD Group	0
SB732461 Non-adjuvanted_HD Group	0
SB732461 Non-adjuvanted_LD Group	2
SB732461 Non-adjuvanted_HD Group	1
SB732461 Non-adjuvanted_LD Group	8
SB732461 Non-adjuvanted_HD Group	9
SB732461 adjuvanted_HD Group	43
SB732461 adjuvanted_LD Group	1
SB732461 adjuvanted_LD Group	3
SB732461 adjuvanted_MD Group	4
SB732461 adjuvanted_HD Group	5
SB732461 adjuvanted_LD Group	45
SB732461 adjuvanted_MD Group	45
SB732461 adjuvanted_HD Group	2
SB732461 adjuvanted_LD Group	2
SB732461 adjuvanted_LD Group	48
SB732461 adjuvanted_MD Group	43
SB732461 adjuvanted_HD Group	42
SB732461 adjuvanted_MD Group	5
SB732461 adjuvanted_HD Group	4
SB732461 Non-adjuvanted_LD Group	6
SB732461 adjuvanted_LD Group	43
SB732461 Non-adjuvanted_MD Group	5
SB732461 adjuvanted_MD Group	37
SB732461 adjuvanted_HD Group	33
SB732461 Non-adjuvanted_LD Group	4
SB732461 adjuvanted_LD Group	7
SB732461 adjuvanted_MD Group	12
SB732461 adjuvanted_HD Group	16
SB732461 Non-adjuvanted_LD Group	7
SB732461 adjuvanted_LD Group	47
SB732461 Non-adjuvanted_MD Group	9
SB732461 adjuvanted_MD Group	41
SB732461 adjuvanted_HD Group	46
SB732461 Non-adjuvanted_LD Group	3
SB732461 Non-adjuvanted_MD Group	1
SB732461 adjuvanted_MD Group	8
SB732461 adjuvanted_HD Group	3
SB732461 adjuvanted_MD Group	49
SB732461 adjuvanted_LD Group	50
SB732461 Non-adjuvanted_HD Group	10
SB732461 Non-adjuvanted_LD Group	1
SB732461 Non-adjuvanted_LD Group	9
SB732461 adjuvanted_LD Group	49
SB732461 adjuvanted_HD Group	47
SB732461 adjuvanted_HD Group	49
SB732461 adjuvanted_MD Group	1
SB732461 Non-adjuvanted_MD Group	0
SB732461 adjuvanted_MD Group	0
SB732461 adjuvanted_HD Group	0
SB732461 Non-adjuvanted_LD Group	10
SB732461 Non-adjuvanted_MD Group	10
SB732461 adjuvanted_MD Group	48
SB732461 adjuvanted_HD Group	48
SB732461 Non-adjuvanted_LD Group	0
SB732461 adjuvanted_HD Group	1

Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6

Intervention	Participants (Count of Participants)
	Haemoglobin72427296				Haemoglobin72427297	Haemoglobin72427298	Haemoglobin72427299	Haemoglobin72427295	Haemoglobin72427290	Monocytes72427299	Monocytes72427295	Monocytes72427290	Monocytes72427296	Monocytes72427297	Monocytes72427298	Sodium72427299	Sodium72427290	Sodium72427298	Sodium72427296	Sodium72427295	Sodium72427297	Potassium72427290	Potassium72427297	Potassium72427299	Potassium72427295	Potassium72427296	Potassium72427298	RBC72427290	RBC72427296	RBC72427298	RBC72427295	RBC72427299	RBC72427297	Lymphocytes72427290	Lymphocytes72427298	Lymphocytes72427296	Lymphocytes72427299	Lymphocytes72427297	Lymphocytes72427295	Platelets72427290	Platelets72427296	Platelets72427298	Platelets72427299	Platelets72427297	Platelets72427295	Urea Nitrogen72427290	Urea Nitrogen72427298	Urea Nitrogen72427296	Urea Nitrogen72427297	Urea Nitrogen72427299	Urea Nitrogen72427295	Hematocrit72427298	Hematocrit72427299	Hematocrit72427295	Hematocrit72427290	Hematocrit72427296	Hematocrit72427297	Creatinine72427290	Creatinine72427297	Creatinine72427299	Creatinine72427296	Creatinine72427295	Creatinine72427298	AST72427298	AST72427299	AST72427290	AST72427296	AST72427297	AST72427295	ALT72427296	ALT72427298	ALT72427290	ALT72427297	ALT72427299	ALT72427295	Neutrophils72427299	Neutrophils72427295	Neutrophils72427298	Neutrophils72427290	Neutrophils72427296	Neutrophils72427297	Basophils72427290	Basophils72427296	Basophils72427297	Basophils72427299	Basophils72427298	Basophils72427295	Eosinophils72427298	Eosinophils72427295	Eosinophils72427290	Eosinophils72427296	Eosinophils72427297	Eosinophils72427299	WBC72427298	WBC72427299	WBC72427290	WBC72427296	WBC72427297	WBC72427295
	Unknwon	Below	Within	Above
SB732461 Non-adjuvanted_LD Group	8
SB732461 adjuvanted_LD Group	41
SB732461 Non-adjuvanted_MD Group	7
SB732461 adjuvanted_MD Group	34
SB732461 Non-adjuvanted_HD Group	6
SB732461 adjuvanted_HD Group	30
SB732461 Non-adjuvanted_LD Group	2
SB732461 adjuvanted_LD Group	8
SB732461 Non-adjuvanted_MD Group	2
SB732461 adjuvanted_MD Group	15
SB732461 adjuvanted_HD Group	18
SB732461 adjuvanted_LD Group	49
SB732461 adjuvanted_MD Group	48
SB732461 adjuvanted_HD Group	47
SB732461 adjuvanted_MD Group	44
SB732461 adjuvanted_MD Group	5
SB732461 adjuvanted_HD Group	45
SB732461 adjuvanted_HD Group	1
SB732461 Non-adjuvanted_LD Group	10
SB732461 adjuvanted_LD Group	48
SB732461 adjuvanted_HD Group	49
SB732461 adjuvanted_HD Group	0
SB732461 adjuvanted_MD Group	2
SB732461 adjuvanted_MD Group	47
SB732461 adjuvanted_HD Group	46
SB732461 adjuvanted_MD Group	1
SB732461 adjuvanted_MD Group	0
SB732461 adjuvanted_MD Group	49
SB732461 Non-adjuvanted_HD Group	8
SB732461 Non-adjuvanted_HD Group	2
SB732461 Non-adjuvanted_HD Group	1
SB732461 Non-adjuvanted_HD Group	7
SB732461 Non-adjuvanted_HD Group	0
SB732461 adjuvanted_MD Group	6
SB732461 adjuvanted_HD Group	4
SB732461 Non-adjuvanted_MD Group	8
SB732461 adjuvanted_MD Group	43
SB732461 adjuvanted_HD Group	44
SB732461 adjuvanted_LD Group	46
SB732461 adjuvanted_HD Group	48
SB732461 adjuvanted_LD Group	3
SB732461 adjuvanted_LD Group	1
SB732461 Non-adjuvanted_MD Group	1
SB732461 adjuvanted_HD Group	2
SB732461 Non-adjuvanted_LD Group	1
SB732461 adjuvanted_LD Group	2
SB732461 adjuvanted_MD Group	7
SB732461 Non-adjuvanted_LD Group	9
SB732461 adjuvanted_LD Group	47
SB732461 Non-adjuvanted_MD Group	9
SB732461 adjuvanted_MD Group	42
SB732461 adjuvanted_HD Group	42
SB732461 Non-adjuvanted_LD Group	0
SB732461 adjuvanted_LD Group	0
SB732461 Non-adjuvanted_MD Group	0
SB732461 adjuvanted_HD Group	3

Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9

Intervention	Participants (Count of Participants)
	Haemoglobin72427290				Haemoglobin72427299	Haemoglobin72427298	Haemoglobin72427295	Haemoglobin72427297	Haemoglobin72427296	Monocytes72427297	Monocytes72427298	Monocytes72427299	Monocytes72427295	Monocytes72427296	Monocytes72427290	Sodium72427298	Sodium72427295	Sodium72427290	Sodium72427297	Sodium72427299	Sodium72427296	Potassium72427297	Potassium72427298	Potassium72427295	Potassium72427299	Potassium72427290	Potassium72427296	RBC72427297	RBC72427298	RBC72427295	RBC72427290	RBC72427299	RBC72427296	Lymphocytes72427290	Lymphocytes72427296	Lymphocytes72427297	Lymphocytes72427298	Lymphocytes72427295	Lymphocytes72427299	Platelets72427296	Platelets72427297	Platelets72427298	Platelets72427299	Platelets72427290	Platelets72427295	Urea Nitrogen72427290	Urea Nitrogen72427296	Urea Nitrogen72427299	Urea Nitrogen72427298	Urea Nitrogen72427295	Urea Nitrogen72427297	Hematocrit72427298	Hematocrit72427299	Hematocrit72427296	Hematocrit72427290	Hematocrit72427297	Hematocrit72427295	Creatinine72427298	Creatinine72427295	Creatinine72427299	Creatinine72427297	Creatinine72427290	Creatinine72427296	AST72427295	AST72427297	AST72427296	AST72427290	AST72427298	AST72427299	ALT72427298	ALT72427299	ALT72427297	ALT72427295	ALT72427290	ALT72427296	Neutrophils72427290	Neutrophils72427297	Neutrophils72427299	Neutrophils72427295	Neutrophils72427296	Neutrophils72427298	Basophils72427290	Basophils72427296	Basophils72427297	Basophils72427298	Basophils72427299	Basophils72427295	Eosinophils72427290	Eosinophils72427296	Eosinophils72427299	Eosinophils72427297	Eosinophils72427298	Eosinophils72427295	WBC72427290	WBC72427296	WBC72427297	WBC72427298	WBC72427299	WBC72427295
	Unknown	Within	Below	Above
SB732461 adjuvanted_LD Group	47
SB732461 adjuvanted_LD Group	32
SB732461 Non-adjuvanted_MD Group	8
SB732461 adjuvanted_MD Group	38
SB732461 Non-adjuvanted_HD Group	6
SB732461 adjuvanted_HD Group	35
SB732461 adjuvanted_LD Group	17
SB732461 Non-adjuvanted_MD Group	2
SB732461 adjuvanted_MD Group	11
SB732461 Non-adjuvanted_HD Group	3
SB732461 adjuvanted_HD Group	13
SB732461 adjuvanted_HD Group	2
SB732461 adjuvanted_LD Group	46
SB732461 adjuvanted_MD Group	48
SB732461 adjuvanted_LD Group	3
SB732461 adjuvanted_LD Group	49
SB732461 Non-adjuvanted_MD Group	1
SB732461 adjuvanted_MD Group	3
SB732461 Non-adjuvanted_LD Group	9
SB732461 Non-adjuvanted_MD Group	9
SB732461 adjuvanted_MD Group	47
SB732461 adjuvanted_HD Group	44
SB732461 Non-adjuvanted_LD Group	1
SB732461 adjuvanted_LD Group	0
SB732461 adjuvanted_LD Group	48
SB732461 Non-adjuvanted_HD Group	8
SB732461 adjuvanted_HD Group	3
SB732461 adjuvanted_HD Group	0
SB732461 adjuvanted_MD Group	50
SB732461 adjuvanted_HD Group	46
SB732461 adjuvanted_MD Group	0
SB732461 Non-adjuvanted_HD Group	1
SB732461 Non-adjuvanted_LD Group	0
SB732461 Non-adjuvanted_MD Group	0
SB732461 adjuvanted_MD Group	1
SB732461 adjuvanted_HD Group	1
SB732461 Non-adjuvanted_LD Group	10
SB732461 Non-adjuvanted_MD Group	10
SB732461 adjuvanted_MD Group	49
SB732461 Non-adjuvanted_HD Group	9
SB732461 adjuvanted_HD Group	45
SB732461 Non-adjuvanted_HD Group	0
SB732461 adjuvanted_LD Group	2
SB732461 adjuvanted_HD Group	47
SB732461 adjuvanted_LD Group	1
SB732461 adjuvanted_MD Group	2
SB732461 adjuvanted_HD Group	48
SB732461 Non-adjuvanted_LD Group	8
SB732461 adjuvanted_LD Group	45
SB732461 adjuvanted_MD Group	46
SB732461 Non-adjuvanted_LD Group	2
SB732461 adjuvanted_LD Group	4
SB732461 adjuvanted_MD Group	4
SB732461 adjuvanted_HD Group	43

Number of Subjects With Serious Adverse Events (SAEs) and Related SAEs

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. (NCT00434512)
Timeframe: During the whole study period (From Month 0 up to Month 12)

Intervention	Participants (Count of Participants)
	SAEs72427290	SAEs72427291	SAEs72427292	SAEs72427293	SAEs72427294	SAEs72427295	Related SAEs72427290	Related SAEs72427291	Related SAEs72427292	Related SAEs72427293	Related SAEs72427294	Related SAEs72427295
	SAEs
SB732461 Non-adjuvanted_LD Group	0
SB732461 Non-adjuvanted_MD Group	0
SB732461 Non-adjuvanted_HD Group	0
SB732461 adjuvanted_LD Group	2
SB732461 adjuvanted_MD Group	2
SB732461 adjuvanted_HD Group	2
SB732461 adjuvanted_LD Group	0
SB732461 adjuvanted_MD Group	0
SB732461 adjuvanted_HD Group	0

Fever Clearance Time

Fever clearance time is defined as the time from first dosing to the first normal reading of temperature (<37.5°C for axillary/tympanic or <38°C for oral/rectal) for 2 consecutive normal temperature readings taken between 7 and 25 hours apart. (NCT00440999)
Timeframe: Days 0 to 42

Intervention	hours (Median)
Pyronaridine Artesunate	15.8
Chloroquine	23.8

Parasite Clearance Time

Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance is defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart. (NCT00440999)
Timeframe: Days 0 to 42

Intervention	hours (Median)
Pyronaridine Artesunate	23.1
Chloroquine	32.0

Crude Cure Rate on Day 14

Cure rate on Day 14 is defined as the absence of P. vivax parasitaemia on Day 14 irrespective of temperature (axillary, oral, tympanic, rectal) without previously meeting any of the criteria of treatment failure throughout the follow-up period. (NCT00440999)
Timeframe: Day 14

Intervention	Participants (Count of Participants)
	Total cured	Cambodia	India	Indonesia/Maumere	Thailand/Mae Sot	Thailand/Mae Ramat	baseline P. vivax = 250-5,000/uL	baseline P. vivax = >5,000/uL-10,000/uL	baseline P. vivax = >10,000/uL	age ≤ 12 years	age ≥ 12 years	Gender - Male	Gender - Female	Previous P. vivax episode in the past = no	Previous P. vivax episode in the past = yes
Chloroquine	209	73	33	10	46	47	80	59	70	11	198	148	61	93	116
Pyronaridine Artesunate	217	75	33	11	49	50	69	58	89	13	204	164	53	107	110

Crude Cure Rate on Days 21 and 28.

Cure on Day 21 and 28 is defined as the absence of P. vivax parasitaemia on Day 21 and 28 irrespective of temperature (axillary, oral, tympanic, rectal) without previously meeting any of the criteria of treatment failure throughout the follow-up period. (NCT00440999)
Timeframe: Day 21 and 28

Intervention	percentage of cured subjects (Number)
	Cure rate (%) at Day 21	Cure rate (%) at Day 28
Chloroquine	99.5	98.0
Pyronaridine Artesunate	99.5	97.1

Number of Participants With Adverse Events

Number of participants with adverse events, including clinically significant laboratory results, ECG, vital signs or physical examination abnormalities. (NCT00440999)
Timeframe: Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier

Intervention	Participants (Count of Participants)
	Nr subj. with ≥1 AE	Nr subj. with ≥1 treatment-related AE	Nr subj. with ≥1 SAE	Nr subj. with ≥1 treatment-related SAE	Nr subj. with ≥1 severe or life-threatening AE	Nr subj. with ≥1 AE leading to death	Nr subj. ≥1 AE leading to study drug discontinuation	Nr subj. with ≥1 AE leading to study withdrawal
Chloroquine	72	23	0	0	2	0	2	2
Pyronaridine Artesunate	92	27	2	0	0	0	0	0

Percentage of Subjects With Crude and PCR-corrected Cure Rate on Day 42

Cure on Day 42 is defined as the absence of P. vivax parasitaemia on Day 42 irrespective of temperature (axillary, oral, tympanic, rectal) without previously meeting any of the criteria of treatment failure throughout the follow-up period. (NCT00440999)
Timeframe: Day 42

Intervention	percentage of subjects (Number)
	Crude cure rate (%)	PCR-corrected cure rate (%)
Chloroquine	92.1	94.1
Pyronaridine Artesunate	95.5	95.0

Percentage of Subjects With Fever Clearance on Days 1, 2, and 3

Percentage of subjects with fever clearance on Day 1 (24 hours after first dose), Day 2 (48 hours after first dose), and Day 3 (72 hours after first dose). (NCT00440999)
Timeframe: Day 1, 2, and 3

Intervention	percentage of subjects (Number)
	Clearance rate (%) at Day 1 (24h after first dose)	Clearance rate (%) at Day 2 (48h after first dose)	Clearance rate (%) at Day 3 (72h after first dose)
Chloroquine	58.4	88.3	97.4
Pyronaridine Artesunate	78.6	89.9	97.0

Percentage of Subjects With Parasite Clearance on Days 1, 2, and 3

Percentage of subjects with parasite clearance on Day 1 (24 hours after first dose), Day 2 (48 hours after first dose), and Day 3 (72 hours after first dose). (NCT00440999)
Timeframe: Days 1, 2, and 3

Intervention	percentage of subjects (Number)
	Clearance rate (%) at Day 1 (24h after first dose)	Clearance rate (%) at Day 2 (48h after first dose)	Clearance rate (%) at Day 3 (72h after first dose)
Chloroquine	30.6	88.0	96.7
Pyronaridine Artesunate	71.6	99.5	100.0

Percentage of Subjects With PCR-corrected Cure Rate on Days 14, 21, and 28

Cure on Days 14, 21, and 28 is defined as the absence of P. vivax parasitaemia on Days 14, 21, and 28 irrespective of temperature (axillary, oral, tympanic, rectal) without previously meeting any of the criteria of treatment failure throughout the follow-up period. (NCT00440999)
Timeframe: Day 14, 21, and 28

Intervention	percentage of subjects (Number)
	Cure rate (%) at Day 14	Cure rate (%) at Day 21	Cure rate (%) at Day 28
Chloroquine	99.5	99.5	97.9
Pyronaridine Artesunate	100.0	100.0	98.1

Reviews

15 reviews available for chloroquine and Drug-Related Side Effects and Adverse Reactions

Article	Year
Safety profile of COVID-19 drugs in a real clinical setting. European journal of clinical pharmacology, 2022, Volume: 78, Issue:5 Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Dexamethasone; Drug-Related Side Effects and	2022
Systematic Review of Psychiatric Adverse Effects Induced by Chloroquine and Hydroxychloroquine: Case Reports and Population Studies. The Annals of pharmacotherapy, 2023, Volume: 57, Issue:4 Topics: Anxiety; Chloroquine; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; M	2023
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors. Annales medico-psychologiques, 2021, Volume: 179, Issue:2 Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli	2021
What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects. European journal of ophthalmology, 2021, Volume: 31, Issue:2 Topics: Antimalarials; Caregivers; Chloroquine; COVID-19 Drug Treatment; Drug-Related Side Effects and Adver	2021
Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:6 Topics: Antimalarials; Antineoplastic Agents; Cardiovascular Agents; Chloroquine; Drug Repositioning; Drug-R	2015
Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:6 Topics: Antimalarials; Antineoplastic Agents; Cardiovascular Agents; Chloroquine; Drug Repositioning; Drug-R	2015
Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:6 Topics: Antimalarials; Antineoplastic Agents; Cardiovascular Agents; Chloroquine; Drug Repositioning; Drug-R	2015
Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:6 Topics: Antimalarials; Antineoplastic Agents; Cardiovascular Agents; Chloroquine; Drug Repositioning; Drug-R	2015
Cytoplasmic vacuolization during exposure to drugs and other substances. Cell biology and toxicology, 2012, Volume: 28, Issue:3 Topics: Acids; Autophagy; Cation Transport Proteins; Cell Membrane; Cell Membrane Permeability; Chloroquine;	2012
[Toxic effects of medications on the cornea]. Bulletin de la Societe belge d'ophtalmologie, 2007, Issue:304 Topics: Belgium; Chloroquine; Cornea; Corneal Diseases; Cytarabine; Drug-Related Side Effects and Adverse Re	2007
Effects of myotoxins on skeletal muscle fibers. Progress in neurobiology, 1995, Volume: 46, Issue:5 Topics: Chloroquine; Cholinesterase Inhibitors; Colchicine; Drug-Related Side Effects and Adverse Reactions;	1995
Binding of drugs to eye melanin is not predictive of ocular toxicity. Regulatory toxicology and pharmacology : RTP, 1998, Volume: 28, Issue:2 Topics: Animals; Chloroquine; Drug-Related Side Effects and Adverse Reactions; Eye; Humans; Melanins; Pharma	1998
Drug therapy: Disorders of neuromuscular transmission caused by drugs. The New England journal of medicine, 1979, Aug-23, Volume: 301, Issue:8 Topics: Aged; Animals; Anti-Bacterial Agents; Anticonvulsants; Cardiovascular Agents; Chloroquine; Drug-Rela	1979
[Therapy of sarcoidosis]. Archiv fur klinische und experimentelle Dermatologie, 1966, Volume: 227, Issue:1 Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Antineoplastic Agents; Chloroquine; Dru	1966
The eye and adverse drug effects. Some selected considerations. Minnesota medicine, 1972, Volume: 55, Issue:10 Topics: Acetazolamide; Amyl Nitrite; Anesthesia; Chloramphenicol; Chloroquine; Contraceptives, Oral; Dexamet	1972
Drug induced retinopathy. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 1969, Volume: 158 Suppl Topics: Adsorption; Animals; Antineoplastic Agents; Chloroquine; Drug-Related Side Effects and Adverse React	1969
[Effect of drugs on the eye]. Casopis lekaru ceskych, 1970, Mar-06, Volume: 109, Issue:11 Topics: Adrenal Cortex Hormones; Aminohippuric Acids; Antidepressive Agents; BCG Vaccine; Cardiac Glycosides	1970
Effects of drugs on the retina. International ophthalmology clinics, 1971, Volume: 11, Issue:2 Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Chloroquine; Cinchona; Drug-Related Sid	1971

Trials

4 trials available for chloroquine and Drug-Related Side Effects and Adverse Reactions

Article	Year
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors. Annales medico-psychologiques, 2021, Volume: 179, Issue:2 Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli	2021
Artemether-Lumefantrine Versus Chloroquine for the Treatment of Uncomplicated Plasmodium knowlesi Malaria: An Open-Label Randomized Controlled Trial CAN KNOW. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 01-06, Volume: 66, Issue:2 Topics: Adolescent; Adult; Aged; Antimalarials; Artemether, Lumefantrine Drug Combination; Child; Child, Pre	2018
Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine. Clinical and vaccine immunology : CVI, 2014, Volume: 21, Issue:3 Topics: Adjuvants, Immunologic; Adolescent; Adult; AIDS Vaccines; Antimalarials; CD4-Positive T-Lymphocytes;	2014
Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine. Clinical and vaccine immunology : CVI, 2014, Volume: 21, Issue:3 Topics: Adjuvants, Immunologic; Adolescent; Adult; AIDS Vaccines; Antimalarials; CD4-Positive T-Lymphocytes;	2014
Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine. Clinical and vaccine immunology : CVI, 2014, Volume: 21, Issue:3 Topics: Adjuvants, Immunologic; Adolescent; Adult; AIDS Vaccines; Antimalarials; CD4-Positive T-Lymphocytes;	2014
Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine. Clinical and vaccine immunology : CVI, 2014, Volume: 21, Issue:3 Topics: Adjuvants, Immunologic; Adolescent; Adult; AIDS Vaccines; Antimalarials; CD4-Positive T-Lymphocytes;	2014
Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PloS one, 2011, Jan-18, Volume: 6, Issue:1 Topics: Adolescent; Adult; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Chloroquine; Do	2011

Other Studies

47 other studies available for chloroquine and Drug-Related Side Effects and Adverse Reactions

Article	Year
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). Journal of medicinal chemistry, 2008, Jun-12, Volume: 51, Issue:11 Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Bi	2008
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des	2011
In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets. Journal of medicinal chemistry, 2012, Jan-12, Volume: 55, Issue:1 Topics: Animals; Cattle; Cells, Cultured; Computer Simulation; Cornea; Drug-Related Side Effects and Adverse	2012
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS computational biology, 2011, Volume: 7, Issue:12 Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da	2011
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme	2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily	2013
Adverse drug reactions to chloroquine/hydroxychloroquine in combination with azithromycin in COVID-19 in-patients: data from intensive pharmacovigilance in Morocco, 2020. Naunyn-Schmiedeberg's archives of pharmacology, 2023, Volume: 396, Issue:12 Topics: Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug-Related Side E	2023
Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype? Autophagy, 2020, Volume: 16, Issue:12 Topics: Anti-Inflammatory Agents; Antiviral Agents; Autophagy; Chloroquine; COVID-19; COVID-19 Drug Treatmen	2020
Chloroquine in fighting COVID-19: good, bad, or both? Autophagy, 2020, Volume: 16, Issue:12 Topics: Autophagy; Cardiovascular Diseases; China; Chloroquine; Clinical Trials as Topic; COVID-19; COVID-19	2020
Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports. Drug safety, 2020, Volume: 43, Issue:12 Topics: Abdominal Pain; Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agent	2020
Adverse effects of hydroxychloroquine and azithromycin on contractility and arrhythmogenicity revealed by human engineered cardiac tissues. Journal of molecular and cellular cardiology, 2021, Volume: 153 Topics: Anti-Bacterial Agents; Antimalarials; Arrhythmias, Cardiac; Azithromycin; Chloroquine; COVID-19 Drug	2021
Reported Adverse Drug Reactions Associated With the Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic. Annals of internal medicine, 2021, Volume: 174, Issue:6 Topics: Chloroquine; COVID-19 Drug Treatment; Drug-Related Side Effects and Adverse Reactions; Female; Human	2021
Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study. Journal of the American Academy of Dermatology, 2018, Volume: 78, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antimalarials; Chloroquine; Drug Substitution; Drug-Related Side Eff	2018
Prevalence and risk factors associated to pruritus in Plasmodium vivax patients using chloroquine in the Brazilian Amazon. Acta tropica, 2013, Volume: 128, Issue:3 Topics: Adolescent; Adult; Aged; Antimalarials; Brazil; Child; Child, Preschool; Chloroquine; Cross-Sectiona	2013
In vitro sensitivity of Plasmodium falciparum field isolates to extracts from Cameroonian Annonaceae plants. Parasitology research, 2012, Volume: 110, Issue:1 Topics: Animals; Annonaceae; Antimalarials; Cameroon; Chloroquine; Drug Interactions; Drug-Related Side Effe	2012
Suicide by chloroquine. Annales de la Societe belge de medecine tropicale (1920), 1958, Jun-30, Volume: 38, Issue:3 Topics: Chloroquine; Drug-Related Side Effects and Adverse Reactions; Humans; Suicide	1958
Fatal acute chloroquine poisoning in children. Pediatrics, 1961, Volume: 27 Topics: Child; Chloroquine; Drug-Related Side Effects and Adverse Reactions; Humans; Infant; Poisoning	1961
Anticipation of chloroquine retinopathy. Lancet (London, England), 1962, Jun-02, Volume: 1, Issue:7240 Topics: Chloroquine; Drug-Related Side Effects and Adverse Reactions; Retina	1962
SCREENING TEST FOR CHLOROQUINE RETINOPATHY. Lancet (London, England), 1964, Jul-04, Volume: 2, Issue:7349 Topics: Chloroquine; Drug-Related Side Effects and Adverse Reactions; Electrodiagnosis; Ophthalmology; Retin	1964
SCREENING TEST FOR CHLOROQUINE RETINOPATHY. Lancet (London, England), 1964, Jul-04, Volume: 2, Issue:7349 Topics: Antimalarials; Chloroquine; Drug-Related Side Effects and Adverse Reactions; Electrodiagnosis; Ophth	1964
SCREENING TEST FOR CHLOROQUINE RETINOPATHY. Lancet (London, England), 1964, Jun-20, Volume: 1, Issue:7347 Topics: Chloroquine; Drug-Related Side Effects and Adverse Reactions; Electrodiagnosis; Ophthalmology; Retin	1964
[EYE MANIFESTATIONS IN CHLOROQUINE POISONING]. Belgisch tijdschrift voor geneeskunde, 1965, Apr-01, Volume: 21 Topics: Chloroquine; Drug-Related Side Effects and Adverse Reactions; Eye Manifestations; Poisoning; Toxicol	1965
[CHLOROQUINE RETINOPATHY]. Nederlands tijdschrift voor geneeskunde, 1965, Mar-06, Volume: 109 Topics: Chloroquine; Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Retina; Retinal Diseases	1965
Effects of an overdose of chloroquine in a pregnant woman. The American journal of tropical medicine and hygiene, 1955, Volume: 4, Issue:2 Topics: Chloroquine; Drug Overdose; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Pregnan	1955
Chloroquine retinopathy. American journal of ophthalmology, 1962, Volume: 53 Topics: Chloroquine; Drug-Related Side Effects and Adverse Reactions; Humans; Retina; Retinal Diseases	1962
Drug interactions and pharmacogenetic reactions are the basis for chloroquine and mefloquine-induced psychosis. Medical hypotheses, 2006, Volume: 67, Issue:5 Topics: Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chloroquine; Drug Interactio	2006
Pigmentation of the cornea: a review and classification. Annals of ophthalmology, 1983, Volume: 15, Issue:11 Topics: Adult; Child; Chloroquine; Chlorpromazine; Corneal Diseases; Drug-Related Side Effects and Adverse R	1983
Evaluation of the cytotoxicity of selected systemic and intravitreally dosed drugs in the cultures of human retinal pigment epithelial cell line and of pig primary retinal pigment epithelial cells. Toxicology in vitro : an international journal published in association with BIBRA, 2002, Volume: 16, Issue:2 Topics: Animals; Cell Division; Cell Survival; Cells, Cultured; Chloroquine; Dose-Response Relationship, Dru	2002
Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. American journal of ophthalmology, 2002, Volume: 133, Issue:5 Topics: Aged; Antirheumatic Agents; Chloroquine; Dermatologic Agents; Drug-Related Side Effects and Adverse	2002
Ototoxicity of commonly used pharmaceutical preparations. Nigerian medical journal : journal of the Nigeria Medical Association, 1979, Volume: 9, Issue:1 Topics: Adolescent; Adult; Ampicillin; Antihypertensive Agents; Antineoplastic Agents; Aspirin; Child; Chlor	1979
[Neurogenic symptoms for the early diagnosis of adverse drug effects]. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1976, Volume: 82 Pt 1 Topics: Anti-Bacterial Agents; Anticoagulants; Basal Ganglia Diseases; Chloroquine; Cortisone; Depression; D	1976
Law in brief: liability for drug reactions. Hospitals, 1976, Jan-01, Volume: 50, Issue:1 Topics: Chloramphenicol; Chloroquine; Contraceptives, Oral; Drug Evaluation, Preclinical; Drug Industry; Dru	1976
Drug use before hospital admission in Zimbabwe. European journal of clinical pharmacology, 1988, Volume: 34, Issue:1 Topics: Analgesics; Anti-Bacterial Agents; Aspirin; Chloroquine; Drug Therapy; Drug-Related Side Effects and	1988
Proceedings: Drug toxicity as related to ocular melanin. Psychopharmacology bulletin, 1974, Volume: 10, Issue:4 Topics: Antipsychotic Agents; Chloroquine; Drug-Related Side Effects and Adverse Reactions; Eye; Eye Manifes	1974
[Side effects of various drugs acting on the eye]. Fortschritte der Medizin, 1972, Jun-01, Volume: 90, Issue:16 Topics: Cardiac Glycosides; Chloroquine; Contraceptives, Oral; Cyproheptadine; Drug-Related Side Effects and	1972
[Iatrogenic cataracts]. Medizinische Klinik, 1974, Oct-18, Volume: 69, Issue:42 Topics: Aged; Anesthetics, Local; Anthelmintics; Azathioprine; Cataract; Chloroquine; Chlorpromazine; Dimeth	1974
Ocular complications of drug therapy. Aerospace medicine, 1972, Volume: 43, Issue:8 Topics: Adrenal Cortex Hormones; Aerospace Medicine; Antimalarials; Chloroquine; Cholinesterase Inhibitors;	1972
Clinical problems related to the use of drugs in malnutrition. The Proceedings of the Nutrition Society, 1974, Volume: 33, Issue:3 Topics: Child; Child Nutritional Physiological Phenomena; Chloramphenicol; Chloroquine; Drug-Related Side Ef	1974
[Ocular adverse effects of generally used drugs]. Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1973, Jul-17, Volume: 62, Issue:29 Topics: Chloroquine; Drug-Related Side Effects and Adverse Reactions; Ethambutol; Eye Diseases; Humans; Indo	1973
Adverse reactions to drugs used in the treatment of tropical diseases. Canadian journal of public health = Revue canadienne de sante publique, 1973, Volume: 64 Topics: Chloroquine; Drug-Related Side Effects and Adverse Reactions; Humans; Parasitic Diseases; Piperazine	1973
[Etiology and pathogenesis of toxic side-effects of drugs on the retina (author's transl)]. Klinische Monatsblatter fur Augenheilkunde, 1973, Volume: 163, Issue:2 Topics: Adrenal Cortex Hormones; Animals; Antineoplastic Agents; Cardiac Glycosides; Cats; Chloramphenicol;	1973
Iatrogenic disease in the treatment of rheumatoid arthritis. Journal of the Medical Association of the State of Alabama, 1971, Volume: 41, Issue:3 Topics: Arthritis, Rheumatoid; Chloroquine; Drug-Related Side Effects and Adverse Reactions; Glucocorticoids	1971
[Drugs and kidney function]. Helvetica medica acta, 1967, Volume: 34, Issue:1 Topics: Analgesics; Anti-Bacterial Agents; Cathartics; Chloroquine; Creatinine; Diuretics; Drug-Related Side	1967
[Critical view on drug therapy for rheumatism]. Zeitschrift fur Rheumaforschung, 1967, Volume: 26, Issue:11 Topics: Analgesics; Animals; Anti-Bacterial Agents; Chloroquine; Drug-Related Side Effects and Adverse React	1967
[Eye diseases caused by drugs]. Nederlands tijdschrift voor geneeskunde, 1970, Jul-04, Volume: 114, Issue:27 Topics: Anti-Bacterial Agents; Chloroquine; Contraceptives, Oral; Drug-Related Side Effects and Adverse Reac	1970
Prolonged pharmacotherapy and the eye. A symposium. Opening remarks. Diseases of the nervous system, 1968, Volume: 29, Issue:3 Topics: Adaptation, Ocular; Chloroquine; Darkness; Drug-Related Side Effects and Adverse Reactions; Eye; Fee	1968
Iatrogenic symptoms in ophthalmology. British medical journal, 1969, Apr-26, Volume: 2, Issue:5651 Topics: Accommodation, Ocular; Chloroquine; Drug-Related Side Effects and Adverse Reactions; Eye Diseases; H	1969